Table of Contents



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM10-K

 

x☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 20222023

 

or

 

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ______________

 

Commission file number: 000-22923

 

INTERNATIONAL ISOTOPES INC.

(Exact name of registrant as specified in its charter)

 

Texas

 

74-2763837

(State or other jurisdiction of incorporation or origination)

 

(IRS Employer Identification No.)

 

4137 Commerce Circle

Idaho Falls,, Idaho

 

83401

(Address of principal executive offices)

 

(Zip code)

 

(208)524-5300

(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Securities registered pursuant to Section 12(g) of the Act:

--------------------------------------------------------------


COMMON STOCK, $.01 PAR VALUE

(Title of Class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o☐ Nox ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o☐ Nox ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesx ☒ No o

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yesx ☒ No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer    o

Accelerated filer    o

Non-Accelerated filerx   ☒ 

Smaller reporting company    x

 

Emerging growth company    o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

1

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. o

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. o

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o☐ Nox ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the average bid and asked price of such common equity at June 30, 2022,2023, the last business day of the registrant’s second fiscal quarter, was approximately $50$13 million. For purposes of this calculation, all directors and executive officers of the registrant and holders of 10% or more of the registrant’s common stock are assumed to be affiliates. This determination of affiliate status is not necessarily conclusive for any other purpose.

 

As of March 3, 2023,27, 2024, the number of shares outstanding of the registrant’s common stock, $.01 par value, was 514,992,771520,081,365 shares.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Certain information called for in Part III of this Annual Report on Form 10-K is incorporated by reference from the registrant’s definitive proxy statement for the 20232024 annual meeting of shareholders, which will be filed with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2022.

2023.

 

2

 

INTERNATIONAL ISOTOPES INC.

 

FORM 10-K

 

TABLE OF CONTENTS

 

  

Page No.

PART I

  
   

Item 1.

Business

4

Item 1A.

Risk Factors

10

Item 1B.

Unresolved Staff Comments

13

Item 2.1C.PropertiesCybersecurity1413

Item 3.2.

Legal ProceedingsProperties

14

Item 3.

Legal Proceedings

14

Item 4.

Mine Safety Disclosures

14

   

PART II

  
   

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

14

15

Item 6.

[Reserved]Reserved

15

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

16

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

24

Item 8.

Financial Statements and Supplementary Data

24

25

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

24

25

Item 9A.

Controls and Procedures

24

25

Item 9B.

Other Information

25

26

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 
   

PART III

  
   

Item 10.

Directors, Executive Officers and Corporate Governance

25

26

Item 11.

Executive Compensation

25

26

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

25

26

Item 13.

Certain Relationships and Related Transactions, and Director Independence

26

27

Item 14.

Principal Accountant Fees and Services

26

27

  

PART IV

 
  

Item 15.

Exhibits, Financial Statement Schedules

26

27

Item 16.

Form 10-K Summary

29

30

Signatures

 30

31

-

 

3

 

Cautionary Note Regarding Forward-Looking Statements

 

This Annual Report on Form 10-K (the “Annual Report”Annual Report) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Annual Report are forward-looking. Words such as: “anticipates,anticipates, “believes,believes, “should,should, “expects,expects, “future”future and “intends”intends and similar expressions identify forward-looking statements. In particular, statements regarding: financial condition, operating results and liquidity, future cash flow from operations, our ability to achieve profitability, the expected growth in business segment revenues, our expansion into new markets, the ability of our products to compete with several larger companies and products, the results of market studies used to support our business model, our anticipated improvement in economic conditions, the expected increased revenue resulting from sales of our U.S. Food and Drug Administration (FDA)-approved sodium iodide drug product, our ability to continue cobalt-60 production, the status of our proposed uranium de-conversion facility, and the sufficiency of our available cash and revenues from operations to meet our operating needs, are forward-looking. Forward-looking statements reflect management’smanagements current expectations, plans or projections and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. Certain risks and uncertainties that could cause actual results to differ significantly from management’smanagements expectations are described in the section entitled “Risk Factors”Risk Factors in this Annual Report. That section, along with other sections of this Annual Report, describes some, but not all, of the factors that could cause actual results to differ significantly from management’smanagements expectations. We do not intend to publicly release any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the risks and other factors set forth in the other reports that we file from time to time with the Securities and Exchange Commission (the “SEC”SEC).

 

PART I

 

Item 1.       BUSINESS

 

General Business and Products Description

 

International Isotopes Inc. (the “Company”, “we”, “us” and “our”) produces an FDA approved generic sodium iodide I-131 drug product, provides radiochemicals for clinical research and life sciences, manufactures a wide range of nuclear medicine calibration and reference standards, provides radiochemicals for clinical research and life sciences, and produces a variety of cobalt-60 products for medical, research, and industrial applications.

We were formed as a Texas corporation in 1995. Our wholly-owned subsidiaries are International Isotopes Idaho Inc., a Texas corporation; International Isotopes Fluorine Products, Inc., an Idaho corporation; International Isotopes Transportation Services, Inc., an Idaho corporation; RadQual, LLC, a limited liability company (RadQual); and TI Services, LLC, a limited liability company (TI Services). Our core business consists of four reportable segments which include: Theranostics Products (formerly called Radiochemical Products,Products), Cobalt Products, Nuclear Medicine Standards, and Fluorine Products.

 

During 2022,2023, we focused our efforts on achieving profitability in each of our core business segments and reached several significant goals. During 2022,2023, we:

 

4 

Increased total company revenues by $1,085,397 or 10%.

 

 

Reached $12.3 million in total revenues which was the largest single year in company history.

Increased sales in our Theranostics Products segment by 13% primarily through increases in sales of our FDA approved generic sodium iodide I-131 drug product.

Increased sales in our Nuclear Medicine Standards by 10%.

Developed several new products for our Nuclear Medicine products segment and expanded our range of products in this segment including Positron Emission Tomography (PET) imaging standards.

Purchased medical devices and related assets and intellectual property rights from AMICI, Inc. that we plan to expand into an additional business segment, "Medical Devices" starting in 2024.

Pursuant to an option agreement entered into in October 2022, we worked to complete an asset sales agreement to sell our unused assets in our FEP business segment. In February 2024, we entered an Asset Purchase Agreement to sell these assets for a total of $12.5 million. The transaction is expected to close in approximately 12 to 24 months, subject to satisfaction of certain closing conditions.

4

In 2023,2024, we plan to continue efforts to further expand and improve upon our operations in our core business segments. Additionally, we are planning an additional business segment for "Medical Devices". We intend to continue to invest in these segments and work to pursue product development, reduce production costs, and expand sales in each of our segments. The following paragraphs provide a brief description of each of our business segments. Certain financial information with respect to each of our business segments, including revenues from external customers, a measure of profit or loss, and total assets, is set forth in Note 15 to our Consolidated Financial Statements which begin on page F-7.

 

Theranostics Products (formerly Radiochemical ProductsProducts)

 

This segment includes the production and distribution of various isotopically pure radiochemicals for medical, industrial, and research applications. These products are either directly produced by us or are purchased in bulk from other producers and distributed by us in customized packages and chemical forms tailored to meet customer and market demands. In February 2020, we receivedOur FDA approval of our ANDA for ourapproved generic sodium iodide I-131 drug product. Our generic sodium iodide drug product is the only generic product of this type manufactured in the U.S. and offers customers an attractive domestic alternative to the single existing foreign commercial drug manufacturer. We have two suppliers of sodium iodide I-131 from whom we purchased material during 20212022 and 20222023 in order to produce this product in the most reliable manner possible. Going forward this segment will be called the Theranostics Products segment.

 

Cobalt Products

 

Our cobalt products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy as well as various industrial applications, and recycling of expended cobalt sources.

 

The year-over-year demand for cobalt products has remained strong as a result of the introduction of several new types of cobalt therapy units and we have continued to see demand for cobalt-manufactured products for those devices. We have explored, and intend to continue to explore, opportunities to further develop cobalt products and sales on an on-going basis. The production, use, transport, and import/export of these products are all heavily regulated, but we have developed an experienced staff of technicians, shipping specialists, and supervisors as part of our efforts to comply with the regulations and support cost effective, timely delivery of these products.

 

At the present time, we are the sole purchaser of high activity cobalt from any of the DOE reactors in the U.S. There are a few other cobalt source manufacturers in North America. We believe both our product and service provide us with a competitive edge in competing with these other manufacturers.

 

Nuclear Medicine Standards

 

This segment consists of the manufacture and sale through our wholly-owned subsidiary, RadQual, of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. Our nuclear medicine standards products include flood sources, dose calibrators, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and a host of specialty design items. These products are manufactured and distributed by our wholly-owned subsidiary, RadQual. In July 2021, we purchased the remaining 75.5% interest of RadQual. Prior this purchase we were one of two managing members of RadQual and had significant influence in management decisions with regard to RadQual’s business operations. Following the July 2021 acquisition, we have now fully consolidated the income and expenses from both RadQual LLC and TI Services.

 

There are over 5,000 nuclear medicine centers in the United States (U.S.) that require nuclear medicine products on a regular repeat basis. We have been manufacturing these products for RadQual since 2001. Most nuclear medicine product sales are to U.S. customers. However, in recent years, because of stronger marketing efforts, we have seen an increase in foreign sales, as shown in Note 14 to the accompanying audited financial statements. All these products contain radioactive isotopes that decay at a predictable rate. Therefore, customers are required to periodically replace most of these products when they reach the end of their useful lives. The useful life of these products varies depending on the isotope used in manufacture, but in most cases averages eighteen months to two years. Most of theThe various isotopes used in manufacturing these nuclear medicine products are available from variousseveral sources world-wide, and we are not dependent on a single supplier.continually working to develop multiple sources of each isotope. In addition to the products themselves, we have developed a complete line of specialty packaging for the safe transportation and handling of these products.

 

This segment now includes source disposal activities that were previously reported in the discontinued Radiological Services business segment.

Radiological Services

We discontinued separate reporting

5

 

Fluorine Products and the Planned Uranium De-Conversion Facility

 

We established the fluorine products business segment in 2004 to support production and sale of various fluoride gases produced using our Fluorine Extraction Process (FEP)("FEP"). FEP was intended to be completed in conjunction with the operation of a proposed depleted uranium (DUF6)("DUF6") de-conversion facility in Lea County, New Mexico. DUF6 is the waste by-product of uranium enrichment, and any uranium enrichment facility will create very large quantities of DUF6. In October 2012, we received a construction and operating license from the NRCU.S. Nuclear Regulatory Commission ("NRC") for the planned facility. Changes in the nuclear industry near the end of 2013, however, significantly reduced commercial demand for this type of facility. Therefore, we suspended all further development work on the project. We still anticipate a potential future need for a depleted uranium conversion facility and therefore, we are keepinghave kept all licenses and permits current.

 

In connection with the proposed de-conversion facility, Lea County, New Mexico transferred propertyOn February 8, 2024, we entered into a definitive agreement to us under the provisionssell all of the New Mexico Local Economic Development Act, Project Participation Agreement (PPA) as a location for construction of the facility. Under the original agreement, we were obligated to meet certain performance objectives for construction start and staffing levels. Because of the project delay we did not meet those objectives. We plan to continue to work with Lea County to execute a modificationour assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility ("DUF6 Asset Sale"). We expect to close the agreement at some future point shouldwithin 12 to 24 months of signing. Closing is contingent on various conditions being met, including approvals and agreements by the project move forward. If we do not extend or modify the commitment dates in a modified agreement then we may either purchase or re-convey the property to Lea County, New Mexico. If we do not retain title to the property, it could have a material adverse impact on future plans for the project.NRC and other third parties.

 

Industry Overview, Target Markets, and Competition

 

The industries and markets that require or involve the use of radioactive material are diverse. Our current core business operations involve products that are used in a wide variety of applications and in various markets. The following provides an explanation of the markets and competitive factors affecting our current business segments.

Theranostics Products (formerly Radiochemical Products)

In February 2020, our abbreviated new drug application ("ANDA") for a generic radiopharmaceutical sodium iodide drug product was approved by the FDA. This product is approved for use in treatment of hyperthyroidism and carcinoma of the thyroid and is the first and only generic sodium iodide I-131 product approved by the FDA in the U.S. and only generic product of this type manufactured in the U.S. The only other supplier to the U.S. of an FDA approved sodium iodide product comes from a foreign manufacturer.

Since the launch of this drug product in 2020, the corresponding sales have had a significant positive impact on our revenues including 2022 and 2023. We expect this significant growth in sales for this product to continue in 2024 and beyond. We are also considering other generic drug opportunities and plan to expand the range of FDA approved products offered within this business segment in the coming years.

We also supply theranostics Products in bulk form. The markets for most radiochemicals can be highly competitive. The target markets for these products are customers who (1) incorporate them into finished industrial or medical devices; (2) use radioisotope products in clinical trials for various medical applications; or (3) further process and include the radioisotope products into pharmaceutical products approved by the U.S. FDA for labeled use in therapy or imaging.

In February 2022, we sold the improvements and equipment in an expansion that had been constructed to our manufacturing facility for cGMP processing. Using the capital from this sale, we are currently developing a business plan and exploring other opportunities that support our Theranostics and Medical Device segments. We believe that we are uniquely qualified and have a competitive advantage for future opportunities because we have a unique combination of NRC licensing, GMP compliant operating facility, and trained personnel.

Cobalt Products

In 2014, we entered into a 10-year agreement with the DOE utilizing a new cobalt target design for high activity cobalt production to be produced at the Advanced Test Reactor ("ATR"). Due to lower than desired activity rates in the material from the DOE, we bought the low activity targets at a discounted rate. There is a high demand for lower activity cobalt. We have taken shipment of and sold this material throughout 2022 and 2023 and will continue to have supply for at least two more years. We are now working with the DOE on future purchases of both high, medium, and low specific activity cobalt after the expiration of our current DOE agreement. Our cobalt products are used in applications such as radiation therapy, security devices, radiography examination and in some commercial applications. While there are other technologies available to provide external radiation therapy, there are several new devices just gaining market approval that still depend on cobalt sources for their specialized applications.

There has been a significant increase in regulation by the NRC in recent years that has created a significant barrier to new entrants to this market. We expect steady demand for cobalt sealed source products over the next several years but are primarily dependent upon our contract relationship with the DOE for a large portion of our cobalt production supply. An interruption in the operation of the ATR could have a negative impact on our cobalt products business segment.

6

 

Nuclear Medicine Standards

 

Calibration and reference standards are required for the daily operational checks and calibration of the measurement of SPECT and PET imaging devices frequently used in nuclear medicine. Calibration and quality assurance testing are required as a routine part of the normal operations of this equipment to ensure its reliability and accuracy. For years, we have been the exclusive manufacturer of RadQual reference standard products. As RadQual is now our wholly-owned subsidiary, we continue to sell these same RadQual products through distributors who make direct sales in the U.S. and internationally. We directly ship these products to all 50 states and many overseas locations. There is only one other major producer of these products in the world that competes directly with us for these products. Most of the products manufactured by our

competitor are similar in design to our products because all must meet Original Equipment Manufacturer (OEM) dimensional and performance standards. However, we attempt to differentiate our products from our competitor’s products through increased levels of quality control and customer service. We are certified under ISO-9001:2015 and ISO-13485-2016 quality programs that have allowed us to start selling these products into several foreign countries that require this additional quality certification for manufacturers. We use a small number of suppliers for the isotopes and other materials used in manufacturing these nuclear medicine products, but if we were to lose any of these suppliers, in most cases other suppliers would be available. We are also working to expand the number and types of products that are manufactured in this segment and expand our raw product qualified suppliers

Cobalt Products

In 2014, we entered into a new 10-year agreement with the DOE utilizing a new cobalt target design for high activity cobalt production. Because of the lengthy irradiation time required we initially anticipated that cobalt shipments to customers would resume in late 2018. However, due to delays in the ATR operating schedule we were not able to take our first shipment of these targets until March 2020. Due to lower than desired activity rates in the material, we bought the remaining low activity targets at a discounted rate. There is a high demand for lower activity cobalt. We have taken shipment of and sold this material throughout 2021 and 2022 and will continue to have supply for at least two more years. We are now working with the DOE on future purchases of both high and low activity cobalt. Our cobalt products are used in applications such as radiation therapy, security devices, radiography examination and in some commercial applications. While there are other technologies available to provide external radiation therapy, there are several new devices just gaining market approval that still depend on cobalt sources for their specialized applications. There are currently no other producers of high specific activity cobalt in the U.S., however, there are producers of high specific activity material in Canada and several other countries. In addition to us, there is only one other company in the U.S. currently licensed to handle large quantities of cobalt.

There has been a significant increase in regulation by the NRC in recent years that has created a significant barrier to new entrants to this market. We expect steady demand for cobalt sealed source products over the next several years but are primarily dependent upon our contract relationship with the DOE for a large portion of our cobalt production supply. An interruption in the operation of the ATR could have a negative impact on our cobalt products business segment.

Radiochemical Products

In February 2020, our ANDA for a generic radiochemical sodium iodide drug product was approved by the FDA. This product is approved for use in treatment of hyperthyroidism and carcinoma of the thyroid and is the first and only generic sodium iodide I-131 product approved by the FDA in the U.S. and only generic product of this type manufactured in the U.S. The only other supplier to the U.S. of an FDA approved sodium iodide product comes from a foreign manufacturer.

Since the launch of this drug product in 2020, the corresponding sales have had a significant positive impact on our revenues in 2021 and 2022. We expect this significant growth in sales for this product to continue in 2023 and beyond. We are also considering other generic drug opportunities and plan to expand the range of FDA approved products offered within this business segment in the coming years.

We also supply radiochemical products in bulk form. The markets for most radiochemicals can be highly competitive. The target markets for these products are customers who (1) incorporate them into finished industrial or medical devices; (2) use radioisotope products in clinical trials for various medical applications; or (3) further process and include the radioisotope products into pharmaceutical products approved by the U.S. FDA for labeled use in therapy or imaging.

In February 2022, we sold the improvements and equipment in an expansion that had been constructed to our manufacturing facility for cGMP processing. Using the capital from this sale, we are currently developing a business plan and exploring other opportunities that support our current radiopharmaceutical product, produce additional radiopharmaceutical products or explore new contract manufacturing opportunities. We believe that we are uniquely qualified and have a competitive advantage for future opportunities because we have a unique combination of NRC licensing, GMP compliant operating facility, and trained personnel.suppliers.

 

Fluorine Products and the Planned Depleted Uranium De-Conversion Facility

 

Our Fluorine Products segment was developed in conjunction with uranium de-conversion to take advantage of the anticipated need for depleted uranium de-conversion services. During 2013, we curtailed all further work on the de-conversion facility because of a lack of demand for uranium de-conversion services at that time. However,We have continued to maintain the assets and licenses related to our previously planned de-conversion facility. 

On February 8, 2024, we believe that inentered into a definitive agreement to sell all of our assets related to the futureFluorine Products segment ("DUF6 Asset Sale"). We expect to close the agreement within 12 to 24 months. Closing is contingent on various conditions being met, including approvals and agreements by the U.S. Nuclear Regulatory Commission and other third parties.

 

7

 

there will be a demand for this service to address still growing stockpiles of depleted UF6. When that demand occurs, we believe the groundwork we have completed on the depleted uranium de-conversion and fluorine extraction project should put us in a strong position to take advantage of the NRC license that has already been issued for this facility and should serve to justify the financial investment in this uranium de-conversion project in the future.

Government Regulation

 

Licensing

We currently operate under two NRC licenses, one for broad scope operations and another for exempt distribution. Our broad scope license covers calibration and reference standard manufacturing and distribution, radioisotope processing and distribution, large scale cobalt processing and recycle operations, radioactive gemstone processing, environmental sample analysis, certain field service activities, and research and development. The exempt distribution license permits the release and distribution of irradiated gemstones to unlicensed entities in the U.S. All of our existing licenses and permits are adequate to allow current business operations. We do not handle “special nuclear materials” (i.e. nuclear fuels and weapons grade uranium, thorium or plutonium); therefore, our facility is not designated as a “nuclear” facility that would require additional licensing.

 

As a condition of our NRC licenses in Idaho, we are required to provide financial assurance for decommissioning activities. We fulfill this license requirement with a surety bond which names the NRC as beneficiary and is supported by a restricted cash account held in trust by a third party. Similar financial assurances will be required to fund the decommissioning of the proposed de-conversion facility.

In October 2012, we were granted a 40-year construction and operating license by the NRC for our planned depleted uranium de-conversion and fluorine extraction processing facility (the “de-conversion facility”). The de-conversion facility is planned to be located in Lea County, New Mexico. Further engineering work on the proposed de-conversion facility was placed on hold in 2013 until additional contracts for utilization could be obtained. There is no specific timeline required by the NRC for the start of construction on this project. The majority of the pre-construction design, licensing and state permitting has already been completed for the project and a ground water permit from the state of New Mexico remains to be obtained before the plant could begin operation. These licenses for the de-conversion facility are included in the DUF6 Asset Sale as described above.

Regulation of Radioisotope Production Waste

 

All our manufacturing processes generate some radioactive waste. We must handle this waste pursuant to the Low-Level Radioactive Waste (LLRW) Policy Act (LLRW Act), which requires the safe disposal of mildly radioactive materials. The estimated costs for storage and disposal of these materials have been included in the manufacturing and sales price of our products. However, actualActual disposal costs are subject to change at the discretion of the disposal site and are ultimately applied at the time of disposal.sites. We have obtained all necessary permits and approvals for the disposal of our waste materials, and we do not anticipate any negative changes in capacity or regulatory conditions that would limit or restrict our waste disposal capabilities.

 

Nuclear Regulatory Commission Oversight

We operate under two NRC licenses and are subject to NRC oversight and periodic inspections of our operations.

 

Other Regulations

 

We are registered as a medical device manufacturer through the FDA for several of our nuclear medicine reference and calibration standards. We are registered with the U.S. Department of Transportation (DOT) for the shipment of radioactive materials. We also have an NRC license for the import and export of radioactive materials. Because of increasing security controls and regulations, it is likely that we may encounter additional regulations affecting transportation, storage, sale, and import/export of radioactive materials.

 

We are also subject to inspection by the FDA to manufacture our sodium iodide I-131 product in compliance with our ANDA for sodium iodide I-131 and all applicable cGMP requirements for this and other contract manufactured products. We are registered with the FDA as a drug manufacturing facility, and we are subject to periodic and random inspections by the FDA for the continued manufacture of drug products.

 

We are subject to government regulation and intervention both in the U.S. and in all foreign jurisdictions in which we conduct business. Compliance with applicable laws and regulations results in higher capital expenditures and operating costs and changes to current regulations with which we must comply can necessitate further capital expenditures and increases in operating costs to enable continued compliance.

 

8

Environmental Compliance

We are subject to various federal, state, local and foreign government requirements regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. These laws and regulations include, but are not limited to the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), the Resource Conservation and Recovery Act (RCRA) and state statutes such as the Idaho Hazardous Waste Management Act, the LLRW Policy Act, NRC regulations concerning various irradiated, radioactive, and depleted uranium materials, and U.S. DOT regulations concerning shipment of radioactive materials. Certain of these laws and regulations can impose substantial fines and criminal sanctions for violations and require installation of costly equipment or operational changes to limit emissions and/or decrease the likelihood of accidental hazardous substance releases. We have incurred, and expect to continue to incur, capital and operating costs to comply with these laws and regulations. In addition, changes in laws, regulations and enforcement of policies, or the imposition of new clean-up requirements or remedial techniques, could require us to incur costs in the future that would have a negative effect on our financial condition or results of operations.

 

Distribution Methods for Products

 

We sell our products directly to our customers who, in some cases, are both end users and distributors. We use common commercial carriers for delivery of our products.

 

Dependence on Customers

 

Historically, we had been dependent on one customer, RadQual, of which we owned 24.5%, for a significant amount of our gross revenue. In July 2021, we purchased the remaining 75.5% of the ownership interest in RadQual, making it a wholly-owned subsidiary. Our sales to RadQual for 2021 accounted for approximately 28% of our total gross revenue for that year. The change in ownership of RadQual has substantially eliminated any risks associated with having RadQual as a single major customer.

Combined sales, on which we are dependent, to our three largest customers, accounted for 22% of our total gross revenues in 2023 and accounted for 23% of our total gross revenues in 2022 and accounted for 17% of our total gross revenues in 2021.2022.

 

Patents, Trademarks, Licenses and Royalty Agreements

 

In 2004, we obtained certain patents related to the FEP. In 2010, we were granted an additional process patent on the FEP process. During 2012, we were granted additional process patents for the FEP process in the United States. These patents are included in the DUF6 Asset Sale as noted above.

 

In May 2021, we entered into an exclusive licensing agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) for commercial development of a Radioimmuno Assay (RIA) test lit for the detection for SARS COVID-19 virus in the blood. A patent application for this test kit was submitted to the U.S. patent office in March 2021. The useful application and commercial viability of this opportunity will continue to be evaluated,evaluated; however, at the present time we do not plan commercial development of this product but may pursue other related commercial opportunities.

 

Employees

 

As of December 31, 2022,2023, we had 3340 total employees, including 3239 full-time employees.

 

9


 

Available Information

 

Our internet website address is www.intisoid.com.www.intisoid.com. We are subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the Exchange Act). Consequently, we are required to file reports and information with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. These reports and other information concerning us are available free of charge through (i) our website as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC, and (ii) the SEC’s website at www.sec.gov. Information contained on, or accessible through, our website is not incorporated by reference into this Annual Report or other reports filed with the SEC.

 

Item 1A.      RISK FACTORS

 

Readers should carefully consider the following factors that may affect our business, future operating results and financial condition, as well as other information included in this Annual Report. The risks and uncertainties described below are not the only ones the Company faces. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks occur, our business, financial condition and operating results could be materially adversely affected.

 

Risks Related To Our Company

 

We have incurred, and may continue to incur, losses.We have incurred net losses for most fiscal periods since our inception. From inception through December 31, 2022,2023, we have an accumulated deficit (including preferred stock dividends and returns) in the amount of $126,460,843.$127,329,859. The negative cash flow we have sustained has materially reduced our working capital, which in turn could materially and negatively impact our ability to fund future operations and continue to operate as a going concern. Management has taken and continues to take, actions to improve our financial condition and results of operations. The availability of necessary working capital, however, is subject to many factors beyond our control, including, among other things, our ability to obtain financing on favorable terms, or at all, economic cycles, market acceptance of our products, competitors' responses to our products, the intensity of competition in our markets, and the level of demand for our products.

We may need additional financing to continue operations.Because we may continue to experience negative cash flow, we may need to obtain additional financing to continue operations. Management will continue to plan and take actions to improve our financial results which could enhance our ability to obtain financing. However, obtaining additional financing is subject to many factors beyond our control and may not be available to us on acceptable terms or at all. If we are unable to raise additional funds when needed, we could be required to delay development and construction of projects, reduce the scope of, abandon or sell some or all our growth projects or default on our contractual commitments in the future, any of which would have a material adverse effect on our business, financial condition and operating results.

Our operations expose us to the risk of material environmental liabilities.  We are subject to potential material liabilities related to the remediation of environmental hazards and to personal injuries or property damages that may be caused by hazardous substance releases and exposures. The materials used in our operations expose us to risks of environmental contamination that could subject us to liability, including remediation obligations that could be very costly. In addition, the discovery of previously unknown contamination could require us to incur costs in the future that would have a negative effect on our financial condition or results of operations. We have a Surety Bond in place supported by funds in a restricted cash account to provide the financial assurance required by the NRC for our Idaho facility license for decommissioning and a similar mechanism will be required to fund the decommissioning of the proposed new depleted uranium facility. However, if a contamination event occurred within, or outside of, our facility, we may be financially responsible to remediate such contamination and could have to borrow money or fund the remediation liability from our future revenue. We may not be able to borrow the funds, or have available revenue, sufficient to meet this potential liability, which could have a significant negative impact on our financial condition and results of operations.

 

We are dependent upon key personnel.  Our ongoing operations are currently dependent on Steve T. Laflin,Shahe Bagerdjian, President and Chief Executive Officer. The loss of Mr. LaflinBagerdjian could have a material adverse effect on our business. There is no assurance that we will be able to retain Mr. LaflinBagerdjian or our existing personnel or attract additional qualified employees. The loss of any of our key personnel or an inability to attract additional qualified employees could result in a significant decline in revenue.

 

10


 

General economic conditions in markets in which we do business can impact the demand for our goods and services. Decreased demand for our products and services can have a negative impact on our financial performance and cash flow.  Demand for our products and services, in part, depends on the general economic conditions affecting the countries and industries in which we do business. A downturn in economic conditions in the U.S. or industry that we serve may negatively impact demand for our products and services, in turn negatively impacting our operations and financial results. Further, changes in demand for our products and services can magnify the impact of economic cycles on our businesses.

 

Volatility in raw material and energy costs, interruption in ordinary sources of supply and an inability to recover unanticipated increases in energy and raw material costs from customers could result in lost sales or significantly increase the cost of doing business.  Market and economic conditions affecting the costs of raw materials, utilities, energy costs, and infrastructure required for the delivery of our goods and services are beyond our control and any disruption or halt in supplies, or rapid escalations in costs could affect our ability to manufacture products or to competitively price our products in the marketplace. For instance, an interruption in the supply of isotopes such as cobalt-57, cobalt-60, or iodine-131 could result in lost sales of nuclear medicine and calibration standards sales, cobalt product sales, and sodium iodide I-131 generic drug product. We also purchase some of our radiochemical productstheranostics Products from overseas suppliers and the price of those products could be adversely affected through changes in currency exchange rates.

 

We are subject to extensive government regulation in jurisdictions around the globe in which we do business. Regulations address, among other things, environmental compliance, import/export restrictions, healthcare services, taxes and financial reporting, and can significantly increase the cost of doing business, which in turn can negatively impact our operations, financial results and cash flow.  We are subject to government regulation and intervention both in the United States and in all foreign jurisdictions in which we conduct business. Compliance with applicable laws and regulations results in higher capital expenditures and operating costs and changes to current regulations with which we must comply can necessitate further capital expenditures and increases in operating costs to enable continued compliance. Additionally, from time to time, we may be involved in legal or administrative proceedings under certain of these laws and regulations. Significant areas of regulation and intervention include the following:

 

Radioactive Waste. All our manufacturing processes generate some radioactive waste. For waste that cannot be decayed in storage we must handle this waste pursuant to the LLRW Policy Act, which requires the safe disposal of mildly radioactive materials. The estimated costs for storage and disposal of these materials have been included in the manufacturing and sales price of our products. However, actual disposal costs are subject to change at the discretion of the disposal site and are ultimately applied at the time of disposal.site. An unexpected or material increase in these costs could have a material adverse effect on our financial condition and results of operations.

 

Health Compliance. Health regulations dictated by the United States Occupational Safety and Health Administration and NRC are extensive in our business. There is no assurance that our activities will comply with all applicable health regulations at times and, as a result, may expose us to liability under applicable health regulations. Costs and expenses resulting from such liability may materially negatively impact our operations and financial condition. Overall, health laws and regulations will continue to affect our business worldwide.

 

NRC License Enforcement Actions. The NRC may take enforcement action in the event that we are found to be in violation of NRC regulations or in violation of any of our license requirements. Consequences of violations depend upon the severity of the violations as well as the adequacy and timeliness of corrective actions implemented by the licensee to investigate and correct the cause of the violation and to prevent reoccurrence. The NRC has discretionary authority in the action they choose to take against license violations, but these actions can include civil penalties and restrictions upon licensee operations or license suspension. The imposition of any such penalties and/or restrictions upon our operations or suspension of our license could have a material adverse effect on our financial condition and results of operations.

 

Environmental Regulation. We are subject to various federal, state, local and foreign government requirements regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. These laws and regulations include, but are not limited to CERCLA, the RCRA and state statutes such as the Idaho Hazardous Waste Management Act, the LLRW Policy Act, NRC regulations concerning various irradiated, radioactive, and depleted uranium materials, and U.S. DOT regulations concerning shipment of radioactive materials. Certain of these laws and regulations can impose substantial fines and criminal sanctions for violations and require installation of costly equipment or operational changes to limit emissions and/or decrease the likelihood of accidental hazardous substance releases. We have

11 

incurred, and expect to continue to incur, capital and operating costs to comply with these laws and regulations. In addition, changes in laws, regulations and enforcement of policies, or the imposition of new clean-up requirements or remedial techniques, could require us to incur costs in the future that would have a negative effect on our financial condition or results of operations.

 

11

Import/Export Regulation. We are subject to significant regulatory oversight of our import and export operations due to the nature of our product offerings. Penalties for non-compliance can be significant and violations can result in adverse publicity. Because of increasing security controls and regulations, it is likely that we may encounter additional regulations affecting the transportation, storage, sale, and import/export of radioactive materials.

 

Taxes. We structure our operations to be tax efficient and to make use of tax credits and other incentives. Nevertheless, changes in tax laws, actual results of operations, final audit of tax returns by taxing authorities, and the timing and rate at which tax credits can be utilized can change the rate at which we are taxed, thereby affecting our financial results and cash flow.

 

We may incur material losses and costs as a result of product liability claims that may be brought against us.We face an inherent business risk of exposure to product liability claims in the event that products supplied by us fail to perform as expected or such failures result, or are alleged to result, in bodily injury. Although we have purchased insurance with coverage and in amounts that we believe to be adequate and reasonable in light of our current and planned operations, including our planned uranium de-conversion and fluoride gas production business, if a successful product liability claim were brought against us in excess of our available insurance coverage, it would have a material adverse effect on our business and financial results.

 

Catastrophic events such as natural disasters, pandemics, war and acts of terrorism could disrupt our business or the business of our suppliers or customers, and any such disruptions could have a negative impact on our operations, financial results and cash flow.  Our operations are at all times subject to the occurrence of catastrophic events outside our control, ranging from severe weather conditions such as hurricanes, floods, earthquakes and storms, to health epidemics and pandemics, to acts of war and terrorism. Any such event could cause a serious business disruption that could affect our ability to produce and distribute our products and possibly expose us to third-party liability claims. Additionally, such events could impact our suppliers, thereby causing energy and raw materials to become unavailable to us, and our customers, who may be unable to purchase or accept our products and services. Any such occurrence could have a negative impact on our operations and financial condition.

 

In addition, public health epidemics or outbreaks could adversely impact our business. For example, as a result of the COVID-19 pandemic, we experienced a reduction of sales within our nuclear medicine calibration standards segment and radiochemicals segment during 2021. There was no discernable impact from COVID-19 to our cobalt products business segment during the period. The decrease in sales for 2021 for our nuclear medicine calibration standards segment was the result of the temporary closure of many imaging clinics and suspension of elective or non-essential imaging procedures. During 2021 and 2022, we experienced some global shipping disruption that were partially attributable to the COVID-19 pandemic.

To-date we have not furloughed or terminated any employees as a result of the financial impact of COVID-19. We have seen a limited impact in our raw material supply chain related to the COVID-19. However, from the beginning of 2022, we have experienced an increase in costs for many raw materials and production supplies due to recent cost inflation which have led to increases to costs of goods sold and operating expenses. Although, all segments have been impacted from these cost increases, our nuclear medicine calibration standards segment has been impacted the most. We have seen these increased costs stabilize somewhat; and we are working on counteracting these cost increases with an increase to our produce prices. We believe we can increase our sales prices enough to overcome these cost increases while continuing to maintain and grow our sales.

Our future growth is largely dependent upon our ability to develop new products that achieve market acceptance with acceptable margins.  Our businesses operate in global markets that are characterized by rapidly changing technologies and evolving industry standards. Accordingly, our future growth rate depends upon several factors, including, but not limited to, our ability to (i) identify emerging technological trends in our target end-markets, (ii) develop and maintain competitive products, (iii) enhance our products by adding innovative features that differentiate our products from those of our competitors, and (iv) develop, manufacture, and bring products to market quickly and cost-effectively. Our ability to develop new products based on technological innovation or U.S. FDA approval can affect our competitive position and requires the investment of significant resources. These development efforts divert resources from other potential investments in our businesses, and they may not lead to the development of new products on a timely basis or that meet the needs of our customers as fully as competitive offerings. In addition, the markets for our products may not develop or grow as we currently anticipate. The failure of our technologies or products to gain market acceptance due to more attractive offerings by our competitors could significantly reduce our revenues and adversely affect our competitive standing and prospects.

 

12 

We are dependent on various third parties in connection with our business operations.  The production of high-specific activity cobalt is dependent upon the DOE, and its prime-operating contractor, which controls the Idaho reactor. Current activity at the Idaho ATR may continue to affect the supply of cobalt material needed for the manufacture of cobalt sources. Loss of the ability to use, or cost-effectively use, these irradiation services would significantly impact our cobalt products business segment because there is not currently another reactor available in the U.S. that is capable of providing this type of service for us. Our radiochemical iodine is supplied to us through two supply sources. Unanticipated contract terminations by these suppliers or suppliers the key raw materials of our other products or other third parties would have a material adverse impact on our operations, financial results, and cash flow.

 

We are dependent on a limited number of customers in connection with some of our current business operations. Combined sales to our three top customers accounted for 23%22% and 17%23% of our total gross revenue during 20222023 and 2021,2022, respectively. Although we are making efforts to reduce our dependency on a small number of customers, the loss of any one of these customers could have a significant impact on our future results of operations and financial condition. Unanticipated contract terminations by any of these current customers could have a material adverse impact on operations, financial results, and cash flow.

 

12

We are subject to competition from other companies.  Each of our existing business areas has direct competition from other businesses. High-specific activity cobalt is supplied by other reactor facilities around the world. Nuclear medicine calibration and reference standards are being produced by one other major manufacturer in the U.S. We have one major competitor in the U.S. for our sodium iodide I-131 drug product. Most of our radiochemicals are also manufactured by several other companies in the world. Most of our competitors have significantly greater financial resources that could give them a competitive advantage over us.

 

Risks Related To Our Common Stock

 

Trading in our common stock is limited and the price of our common stock may be subject to substantial volatility.  Our common stock is quoted on the OTCQB Marketplace under the U.S. trading symbol “INIS”. The market for our securities is limited, the price of our stock is volatile, and the risk to investors in our common stock is greater than the risk associated with stock trading on other markets. These factors may reduce the potential market for our common stock by reducing the number of potential investors. This may make it more difficult for investors in our common stock to sell shares to third parties or to otherwise dispose of their shares. This could cause our stock price to decline.

 

We currently do not intend to pay dividends on our common stock.  We do not plan to pay dividends on shares of our common stock in the near future. Consequently, an investor in our common stock can only achieve a return on its investment in us if the market price of our common stock appreciates.

 

We are contractually obligated to issue shares in the future, which will dilute your interest in us. As of December 31, 2022,2023, there were approximately 16,716,00019,372,500 shares of common stock issuable upon the exercise of vested stock options, at a weighted-average exercise price of $.06$.05 per share. An additional 31,942,54434,932,090 shares were reserved for issuance under our equity plans as of December 31, 2022.2023. Our outstanding preferred stock and certain of our outstanding debt is also convertible into shares of our common stock at the holders’ option. In addition, we expect to issue additional options to purchase shares of our common stock to compensate employees, consultants and directors, and we may issue additional shares to raise capital to expand our manufacturing capability, develop additional products, or fund our planned uranium de-conversion plant. Any such issuance will have the effect of further diluting the interest of the holders of our securities.

 

Item 1B.      UNRESOLVED STAFF COMMENTS

 

We are a smaller reporting company, and therefore, are not required to provide the information required by this item.

 

13 

Item 1C.CYBERSECURITY

 

The operation of our business is dependent on the secure functioning our computer infrastructure. This infrastructure is used to maintain key processes including management of sensitive company information and operation of sales, record-keeping, and accounting functions. 

We employ a specialized third-party information technology ("IT") management firm to monitor and manage our cybersecurity functions. Processes employed include real-time monitoring of company communications and IT activities and consultation and risk assessment of company procedures. Additionally, our third-party IT firm provides education to management and employees regarding our specific IT risks. All our employees receive information security training (including data protection and fraud awareness) on an annual basis. Department managers are given additional risk management training as part of periodic management meetings. Our activities are monitored at all times by our IT firm; we regularly meet with our them to review our cybersecurity response plans, discuss any needed updates, and identify risk management actions to be taken. The IT firm reports all matters of cybersecurity including any threats, breaches, or risks directly to our Chief Financial Officer who reports directly to the Chief Executive Officer. Updates regarding cybersecurity are provided to our directors at least annually and as needed for any important developments including cybersecurity breaches and risks.

We carry a cybersecurity insurance policy to help cover any costs that may occur from a cybersecurity incident. Although risks from cybersecurity threats and implementation of our cybersecurity program have not materially affected our business strategy, business operations or our financial condition, a cybersecurity incident could have a material adverse effect in the future if it were to cause business disruption or data loss.

13

Item 2.       PROPERTIES

 

We lease one property which serves as or main corporate headquarters and houses all of our current manufacturing operations for our core business segments. We also hold the conditional title to 640 acres of land in Lea County, New Mexico for the proposed de-conversion facility. The following paragraphs provide a brief summary of these properties.

 

4137 Commerce Circle, Idaho Falls, Idaho – The facility located on this property houses our main corporate headquarters and all of our current manufacturing operations. In January 2020, we entered into a new lease agreement due to new and expanded facilities made available to us. The initial lease term is until January 2030 and provides an option to renew for an additional 5 years. The lease provides for the Company to expand its leased space as needed into additional areas of the building. The facility was new when leased in March 2001 and remains in excellent condition. We have a right of first refusal on this property that allows us to match any offer to purchase this property.

 

Land - Lea County, New Mexico – In August 2011, we received land from Lea County, New Mexico, pursuant to a PPA, whereby the land was deeded to us for no monetary consideration. In return, we committed to construct a uranium de-conversion and FEP facility on the land. In order to retain title to the property, we were to begin construction of the de-conversion facility no later than December 31, 2014, and complete Phase I of the project and have hired at least 75 persons to operate the facility no later than December 31, 2015, although commercial operations need not have begun by that date. We did not meet the performance milestones set forth in the PPA and we executed a modification to the agreement extending these due dates to December 31, 2016 and 2017, respectively. We plan to work with Lea County to execute an additional modification to the agreement to further extend these dates once an estimated restart date for the project is determined. If we do not succeed in extending the commitment dates or in reaching performance dates set forth in a modified agreement then we may, at our sole option, either purchase or re-convey the property to Lea County, New Mexico. The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment. We have not recorded the value of this property as an asset and will not do so until such time that sufficient progress on the project has been made to meet our obligations under the agreements for permanent transfer of the title. These land rights are part of the DUF6 Asset Sale as described above.

 

Item 3.       LEGAL PROCEEDINGS

 

We are not a party to any legal proceedings that we believe to be material and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results, financial condition, or cash flows.

 

Item 4.       MINE SAFETY DISCLOSURES

 

Not applicable.

 

14

PART II

 

Item 5.       MARKET FOR REGISTRANT’SREGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock is traded on the OTCQB under the trading symbol “INIS”. The following table shows the high and low prices of our common stock on the OTCQB. The following quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions:

 

OTC Bulletin Board (Symbol “INIS”)OTC Bulletin Board (Symbol “INIS”)

OTC Bulletin Board (Symbol “INIS”)

 
  
HighLow 

High

 

Low

 
Period(US $) 

(US $)

  

(US $)

 
First Quarter 20210.340.04
Second Quarter 20210.150.09
Third Quarter 20210.140.08
Fourth Quarter 20210.110.06
First Quarter 20220.100.08 0.34  0.04 
Second Quarter 20220.100.06 0.15  0.09 
Third Quarter 20220.090.04 0.14  0.08 
Fourth Quarter 20220.070.03 0.11  0.06 

First Quarter 2023

 0.10  0.08 

Second Quarter 2023

 0.10  0.06 

Third Quarter 2023

 0.09  0.04 

Fourth Quarter 2023

 0.07  0.03 

 

14 

Holders of Record

 

As of March 11, 2023,16, 2024, there were 490486 holders of record of our common stock.

 

Dividends

 

We have never paid any cash dividends on our common stock. In the future, and based upon our profit performance, our Board of Directors (the “Board”) will evaluate and determine whether to issue dividends, subject to compliance and limitations under any applicable debt or other financing agreements in effect at that time or retain funds for research and development and expansion of our business. We do not anticipate paying any dividends to shareholders of our common stock for the foreseeable future.

 

Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities

 

None.

 

Purchases of Equity Securities by the Issuer

 

None.

 

Performance Graph

 

We are a smaller reporting company, and therefore, are not required to provide the information required by this item.

 

Item 6.             [RESERVED]RESERVED

 

15

Item 7.       MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our results of operations and financial condition should be read in conjunction with the accompanying financial statements and related notes thereto included in Item 8, “FinancialFinancial Statements and Supplementary Data, within this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategies for our business, statements regarding the industry outlook, our expectations regarding the future performance of our business and the other non-historical statements contained herein are forward-looking statements. See “CautionaryCautionary Note Regarding Forward-Looking Statements. You should also review the “Risk Factors”Risk Factors in Item 1A. of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described herein or implied by such forward-looking statements.

Overview

 

International Isotopes Inc. (the “Company”, “we”, “us” and “our”) produces an FDA approved generic sodium iodide I-131 drug product, manufactures a wide range of nuclear medicine calibration and reference standards, and provides radiochemicals for clinical research and life sciences. The Company also produces a variety of cobalt-60 products and supports clients contract manufacturing of radiopharmaceutical and radiochemical products. A more detailed description of each of these product lines and services along with a description of our business segments can be found in Item 1, “Business” within this Annual Report.

 

During 2022,2023, we focused our efforts on achieving profitability in each of our core business segments and reached several significant goals. During 2022,2023, we:

 

Increased total company revenues by $1,085,397 or 10%.

Reached $12.3 million in total revenues which was the largest single year in company history.

Increased sales in the Theranostics Products segment (formerly Radiochemical products segment) by 13% primarily through increases in sales of our FDA approved generic sodium iodide I-131 drug product.

Increased sales in our Nuclear Medicine Standards by 10%.

Developed several new products for our Nuclear Medicine products segment and expanded our range of products in this segment into Positron Emission Tomography (PET) imaging standards.

Purchased medical devices and related assets and intellectual property rights from AMICI, Inc. that we plan to expand into an additional business segment, "Medical Devices" starting in 2024.

Pursuant to an option agreement entered into October 2022, we worked to complete an asset sales agreement to sell our unused assets in our FEP business segment. In February 2024, we entered into an Asset Purchase Agreement to sell these assets for a total of $12.5 million. The transaction is expected to close in approximately 12 to 24 months, subject to satisfaction of certain closing conditions.

 

15 

16

 

As a result of the COVID-19 pandemic, we experienced a reduction of sales within our nuclear medicine calibration standards segment and radiochemicals segment during 2020 and 2021.  There was no discernable impact from COVID-19 to our cobalt products business segment during the same period.  The decrease in sales for 2020 and 2021 for our nuclear medicine calibration standards segment was the result of the temporary closure of many imaging clinics and suspension of elective or non-essential imaging procedures. In 2022, our sales in most segments recovered and we saw very limited continued negative impact related to COVID-19. The sale of radiochemical products increased during the year 2022; however, we believe the increases in revenue for 2022 for nuclear medicine could have been greater in 2022 were it not for the lingering negative impact of COVID-19 in the first quarter of 2022.

To-date we have not furloughed or terminated any employees as a result of the financial impact of COVID-19. The Company has only seen a limited impact in our raw material supply chain related to the COVID-19, primarily some plastics which have been in strong demand for certain types of PPE. Alternative sources of raw materials have been obtained without any interruption to production.  With the heightened concern about corporate liquidity during the COVID-19 pandemic, the Company believes that it has adequate cash to support continuing operations.

 

Business Strategy and Core Philosophies

 

Broadly defined, our business strategy is to continue to build our reputation as a leader in theradioisotope applications, such as theranostics, radiopharmaceutical, radiochemical, medical device, cobalt, and nuclear medicine product industries, and to maximizingmaximize the revenue potential ofacross our generic sodium iodine I-131 product and nuclear medicine standards products.segments. We also intend to continually seek ways to improve our customer service and expand our market share, with the ultimate goal of providing greater return to our shareholders. Specifically, we are continuously working with our customers to improve and develop new products to better serve the needs of the end user which, ultimately, we believe will boost product sales. A key part of our short-term and long-term business strategy is to develop, and marketenter into additional generic drug products, similar tomarkets for our sodium iodide I-131Theranostics, Nuclear Medicine, and Medical Device product and develop additional nuclear medicine standards products that will offer customers high quality, reliable, and affordable products as well as increase our revenues.segments. In addition, we will manage costs and cash reserves and pursue additional financial support that will be structuredflow in such a way to support further expansion of our products and services to exploit additional market opportunities.

 

Our core philosophy is to strive to provide high quality products and services as a profitable and environmentally conscious business, while offering excellent customer service and providing a safe and productive working environment for our employees. We operate in accordance with an ISO Quality Management System and in accordance with all current Good Manufacturing Practices under which we seek to maintain the highest level of quality and continuously improve our product manufacturing processes.

 

Results of Operations

 

Following is a summary of results of operations for 2022:2023:

 

·

Revenue in 20222023 was approximately $11.2$12.3 million, which was a 16%10% increase compared to 2022 and was the largest annual revenue generated in the company’s history;

 

·

Our 20222023 sales in our Theranostics Products (formerly Radiochemical ProductsProducts) increased by approximately 41%13% as compared to 2021;2022;

 

·

Our 20222023 sales in Cobalt Products andour Nuclear Medicine Standards segments decreasedincreased by approximately 15%10% and 1% respectivelysales in our Cobalt Products segment decreased approximately 10% as compared to 2021;2022;

 

·

Our total gross profit rate decreasedincreased to 60% in 2023 from 56% in 2022 from 59% in 2021; and2022;

 

·

Our operating costs for 20222023 increased approximately 17%9% as compared 2021; andto 2022;

 

·

Our 2023 cash provided by operating activities was $582,589;

Our operating loss for 2023 decreased approximately 35% as compared to 2022; and

We had a net loss of $869,016 in 2023 as compared to a net profit of $303,238 in 2022 compared to a net loss of $902,347 in 20212022.

17

 

16 

Year Ended December 31, 20222023 Compared to Year Ended December 31, 20212022

 

The following table presents comparative revenues for the years ended December 31, 20222023 and 2021:2022:

 

Revenues 

For the year ended

December 31, 2022

 

% of Total

Revenues 2022

 

For the year ended

December 31, 2021

 

% of Total

Revenues 2021

  

For the year ended December 31, 2023

  % of Total Revenues 2023  

For the year ended December 31, 2022

  % of Total Revenues 2022 
Radiochemical Products $6,045,767   54% $4,275,044   44%

Theranostics Products

 $6,842,898  56% $6,045,767  54%
Cobalt Products  1,157,536   10%  1,354,517   14% 1,037,073  8% 1,157,536  10%
Nuclear Medicine Standards  3,978,685   36%  4,002,606   42% 4,387,414  36% 3,978,685  36%
Flourine Products  —     0%  29,775   0%     0%     0%
Total Segments $11,181,988   100% $9,661,942   100% $12,267,385   100% $11,181,988   100%

 

Revenues

 

Total revenues in 20222023 were $11,181,988,$12,267,385, compared to $9,661,942$11,181,988 in 2021,2022, which represents an increase of $1,520,046,$1,085,397, or approximately 16%10%. The performance of each segment is discussed in the following paragraphs.

 

 

For the year ended

 

For the year ended

      
Revenues December 31, 2022 December 31, 2021 $ change % change  

For the year ended December 31, 2023

  

For the year ended December 31, 2022

  

$ change

  

% change

 
Radiochemical Products $6,045,767  $4,275,044  $1,770,723   41%

Theranostics Products

 $6,842,898  $6,045,767  $797,131  13%
Cobalt Products  1,157,536   1,354,517   (196,981)  -15% 1,037,073  1,157,536  (120,463) (10)%
Nuclear Medicine Standards  3,978,685   4,002,606   (23,921)  -1% 4,387,414  3,978,685  408,729  10%
Flourine Products  —     29,775   (29,775)  -100%          %
Total Segments  11,181,988   9,661,942   1,520,046   16% 12,267,385  11,181,988  1,085,397  10%
Corporate revenue  —     —     —     —             %
Total Consolidated $11,181,988  $9,661,942  $1,520,046   16% $12,267,385  $11,181,988  $1,085,397  10%

 

RadiochemicalTheranostics Products

 

Sales of radiochemical productstheranostics Products accounted for approximately 54%56% of our sales revenue in 20222023 as compared to 44%54% of our total sales revenue in 2021.2022. Sales in this segment increased by $1,770,723,$797,131, or approximately 41%13% to $6,842,898 in 2023 as compared to $6,045,767 in 2022 as compared to $4,275,044 in 2021.2022. The increase is primarily the result of increased sales of our new generic sodium iodide I-131 drug product which was launched in March 2020. We expect salesproduct.

Sales of our new product to continue to trend upward.

In February 2020, we received approval of an ANDA to the FDA for aFDA-approved generic sodium iodide radiopharmaceuticaldrug product for usemake up the bulk of sales in treatment of hyperthyroidism and carcinoma of the thyroid. We began sales of this product in March 2020, and these sales have had a significant positive impact on our revenues for 2021 and 2022.segment. We expect continued growth in sales for this product in 20222024 and beyond. This is the first of several potential generic drug products we plan to submit to the FDA in the coming years. Within this segment, we also currently distribute sodium iodide (I-131) as a radiochemical product. The radiochemical product is being used for a variety of applications including industrial use and use in investigational and clinical trials. We believe that the product enhancements we have made,market growth, new customers, and entry into new territories, in addition to the generic drug productstheranostics API we plan to submit to the FDA, should increase future sales in this business segment.

 

In 2019, we entered into a manufacturing and supply agreement with a company and completed an expansion

18

 

Cobalt Products

 

Cobalt products sales accounted for approximately 10%8% of our total sales revenue in 20222023 and approximately 14%10% in 2021.2022. Sales in this segment decreased by $196,981,$120,463, or approximately 15%10%, in 20222023 to $1,157,536,$1,037,073, as compared to $1,354,517$1,157,536 in 2021.2022. The decrease in revenue within this segment was the result of decreased Cobalt Sealed Source Manufacturing due to timing of receipt of additional cobalt material from the ATR in 2022,2023, delays in customer contracts for Cobalt Sealed Source Manufacturing, and delays due to maintenance and repairs to our manufacturing equipment. Our sealed source manufacturing generates the majority of our revenue within this segment and sealed source sales depend on our ability to produce or procure cobalt material.

 

17 

In October 2014, we entered into a ten-year agreement with the DOE for the irradiation of cobalt targets. It takes many years to irradiate these cobalt targets to the desired level of activity and we anticipated having high specific activity cobalt available for our customers in 2020. However, the material had lower than expected activity and receipt of material was delayed until about June 2021. At that point the material still had lower than expected activity, and we reached an agreement with the DOE to purchase the lower activity material at a discounted rate. Periodically we have been able to acquire recycled material that can be used to manufacture sealed sources for customers, and in some instances, our customers have supplied their own cobalt material for source fabrication. We will continue to have access to additional low specific activity material produced by the DOE and expect to obtain, process, and sell additional cobalt products as a result during 2023.2024.

 

We have entered into cobalt supply agreements with several customers. The terms of these cobalt contracts require some advance progress payments from each customer. The funding received under these contracts has been recorded as unearned revenue under short- and long-term liabilities in our consolidated financial statements. We recognized some of this revenue in prior years including in 20222023 and 20212022 when we fulfilled contract performance objectives by supplying sealed sources manufactured with cobalt from the ATR or alternate suppliers.

 

Nuclear Medicine Standards

 

Due to decreased activity in the Radiological Services segment, starting January 1, 2022, this segment was reorganized into our Nuclear Medicine Standards segment. Additionally, we reclassified our reporting for 2021 to include all activities for the Radiological Services business segment under the Nuclear Medicine Standards segment.

Sales in the nuclear medicine standards segment accounted for approximately 36% and 40%, of our total sales revenue in 2022both 2023 and 2021, respectively.2022. Sales in this segment decreasedincreased by $23,921,$408,729, or approximately 1%10%, to $4,387,414 in 2023, as compared to $3,978,685 in 2022, as compared to $4,002,606 in 2021.2022. This small decreaseincrease in sales in 20222023 is due to a $93,547 decrease inincreased sales related to the discontinued Radiological Services segment partially offset by an increase of $69,626 in sales related toour RadQual nuclear medicine standards products.

In 2017, affiliates of the Company purchased 75.5% of the member units of RadQualstandard products both domestically and at that time, we were named as one of the managing members of RadQual. Because of this change in member ownership and management, we have consolidated RadQual’s operations within the nuclear medicine segment for financial reporting since that time. For purposes of consolidation, all significant intercompany activity has been eliminated in the reporting process. In July 2021, we acquired the remaining 75.5% of the member units of RadQual. As a result of the acquisition, RadQual and TI Services are now our wholly-owned subsidiaries and are fully consolidated.internationally.

 

We anticipate that our sales of RadQual products will remain strong and that our ownership of RadQual will create significantby creating future opportunities through new product development and expanding markets. Additionally, we will continue to work closely with TI Services using their expertise in marketing and distribution strategies to strengthen nuclear medicine product sales.

 

Radiological Services

Starting in 2022, due to drastically decreased activity in the segment, all remaining activities in our Radiological Services is reported in our Nuclear Medicine Standards segment.

In January 2020, we notified our gemstone processing customer that the service contract with them was being terminated because the volume of gemstones sent for processing did not meet contract minimums. The termination activities and wrap up of this service substantially occurred in 2021 and the Company saw a steady decline in revenue from this service as production was wrapped up. In the first half of 2022, we converted the spaces in the facility that were previously used to perform this contract work into expanded Nuclear Medicine new product manufacturing. The loss in revenue expected from termination of the gemstone processing agreement is expected to be more than compensated for by the expansion of new nuclear medicine source products.

Revenue from field service work for the DOE had accounted for the majority of revenue in this segment. However, Radiological Field Services work was terminated in 2020 and we did not generate any Radiological Field Services revenue in 2021 or 2022. We have removed this type of activity from our NRC license and do not expect to perform this in future years.

We continue to engage in source disposal activities and have begun reporting these activities under the Nuclear Medicine Standards segment starting January 1, 2022. Additionally, we reclassified our reporting for 2021 to include all activities for the Radiological Services business segment under the Nuclear Medicine Standards segment.

18 

Fluorine Products

 

In 2023 and 2022, we had no revenues related to Fluorine Products as compared to $29,775 in 2021. These revenues were related to an agreement to provide engineering and technical assistance services related toProducts. Work on our fluorine products’ intellectual property. We did not have any revenue from this agreement in 2022. In October 2022, we entered into an option agreement with a Company to sellde-conversion facility project that is the NRC license and other assets related toentirety of this business area. The agreement gives the buyer up to 18 months to purchase these assets. Work on this project hadsegment has been on hold since 2013 because of a slowdown in the nuclear industry that specifically impacted fuel cycle facilities. Until suchSince that time, that we execute the asset sales agreement we will limithave limited our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials. In February 2024, we entered into an Asset Purchase Agreement with a Company to sell the NRC license and other assets related to this business area ("DUF6 Asset Sale"). We expect to close the DUF6 Asset Sale in approximately 12 to 24 months, subject to satisfaction of certain closing conditions.

 

During 2021,2023, we incurred $144,860$113,019 of planning and other expenses related to the de-conversion project, as compared to $150,196$144,860 in 2021.2022. This is a decrease of $5,336,$31,841, or approximately 4%22%, and is the result of decreased professional services allocated to this project in 2022.2023. The largest expense in this business segment is $104,379, approximately 72%92% of the total expenses for 2022,2023, for the amortization of our NRC license for this project. We expect that our costs in the future will be limited to essential items such as continued interactions with our customers, the state of New Mexico, and Lea County, New Mexico. If we are able to close the DUF6 Asset Sale as expected, we anticipate dissolving our Flourine Products segment. 

19

 

Cost of Revenues and Gross Profit

 

Cost of revenues for 20222023 was $4,891,927$4,888,409 as compared to $3,924,142$4,891,927 in 2021, an increase2022, a decrease of $967,785,$3,518, or 25%less than 1%. Gross profit percentage decreasedincreased to 60% for 2023, from 56% for 2022, from 59% in 2021.2022. The following table presents revenues and cost of revenues information:

 

 

For the year ended

December 31, 2022

 

% of Total

Revenues 2022

 

For the year ended

December 31, 2021

 

% of Total

Revenues 2021

  

For the year ended December 31, 2023

  % of Total Revenues 2023  

For the year ended December 31, 2022

  % of Total Revenues 2022 
Total Revenues $11,181,988   100% $9,661,942   100% $12,267,385  100% $11,181,988  100%
Cost of Revenues                 
Radiochemical Products $2,217,468   20% $1,698,124   18%

Theranostics Products

 $2,370,048  19% $2,217,468  20%
Cobalt Products  577,417   5%  546,043   6% 482,670  4% 577,417  5%
Nuclear Medicine Standards  2,097,042   19%  1,679,975   17% 2,035,691  17% 2,097,042  19%
Fluorine Products  —     —     —     —        %     %
Total Segments $4,891,927   44% $3,924,142   41% $4,888,409   40% $4,891,927   44%
                 
Gross Profit $6,290,061      $5,737,800      $7,378,976     $6,290,061    
Gross Profit %      56%      59%    60%    56%
  967,785   25%  2,956,357      

 

During 2022,2023, we continued to monitor and control direct costs. Raw materials used in our radiochemical productstheranostics Products and nuclear medicine standards represented the bulk of direct costs for 2022.2023. In each of these business segments, we have purchase agreements in place with suppliers to obtain optimum pricing. Periodically, the cost increasescan increase for these raw materials or we may also use alternate supply sources for our material which might not carry pricing as favorable as our contracted suppliers.

 

The decreaseincrease in gross profit percentage in 20222023 is a result of increased overall sales activity, increased sales prices, and better cost in raw materialcontrols. Additionally, we have worked to find more effective cost controls and supplies in our Nuclear Medicine Standards segment driven by recent cost inflation. We have seen these increased costs stabilize somewhat; and we are working on further offsetting these cost increases with increases to our product prices. We believe we can increase our sales prices enough to overcome these cost increases while continuing to be competitive and maintain sales growth.overall utilization of our raw materials.

20

 

Operating Costs and Expenses

 

Total operating costs and expenses for 20222023 were $7,492,958,$8,155,275, as compared to $6,418,592$7,492,958 in 2021.2022. This is an increase of $1,074,366,$662,317, or approximately 17%9%.

 

The following table presents operating costs and expenses for 20222023 as compared to 2021:2022:

 

  

For the year ended

December 31, 2022

  

For the year ended

December 31, 2021

  % change  $ change 
Operating Costs and Expenses:                
Salaries and Contract Labor $3,390,652  $2,687,735   26% $702,917 
General, Administrative and Consulting  3,568,590   3,459,143   3%  109,447 
Research and Development  533,716   271,714   96%  262,002 
Total operating expenses $7,492,958  $6,418,592   17% $1,074,366 

19 

  

For the year ended December 31, 2023

  

For the year ended December 31, 2022

  

% change

  

$ change

 

Operating Costs and Expenses:

                

Salaries and Contract Labor

 $4,032,155  $3,390,652   19% $641,503 

General, Administrative and Consulting

  3,545,766   3,568,590   (1)%  (22,824)

Research and Development

  577,354   533,716   8%  43,638 

Total operating expenses

 $8,155,275  $7,492,958   9% $662,317 

 

Salaries and contract labor expense increased by $702,917,$641,503, or approximately 26%19%, which was the result of an increased number of employees, and increases to labor rates.rates, and temporary increase in executive salaries during our CEO transition period. In addition, non-cash equity compensation expense recorded for the year ended December 31, 2022,2023, was $352,458$464,041 as compared to $84,564$352,458 for the same period in 2021.2022. This expense is an increase of $267,894, or approximately 317%, and is the result offor equity compensation recorded for outstanding stock options and restricted stock units granted to directors, officers, and employees.

 

General administrative and consulting expenses increaseddecreased less than 1% to $3,545,766 in 2023, as compared to $3,568,590 in 2022, as compared to $3,459,143 in 2021, an increase of $109,447, or approximately 3%. This increase is due to periodic waste disposal costs of $329,237 in 2022 with no such cost in 2021.2022. Research and development expense was $577,354 for 2023, compared to $533,716 for 2022, compared to $271,714 for 2021.2022. This is an increase of $262,002,$43,638, or approximately 96%8%. This increase in research and development expense was the result of increased costs associated with product development in our RadiochemicalTheranostics and Nuclear Medicine Standards business segments.

During both 2022 and 2021, we limited further investment in the planned de-conversion facility and limited further spending on the project only for expenses necessary to maintain licensing, continue interactions with Lea County, New Mexico, and supporting a due diligence review of the project by a company interested in purchasing these project assets. We will continue to delay further engineering work on the de-conversion project until we are able to secure additional contracts for de-conversion services.

 

Other Income (Expense)

 

The following table presents other income (expense) for 20222023 as compared to 2021:2022:

 

 

For the year ended

December 31, 2022

 

For the year ended

December 31, 2021

  

For the year ended December 31, 2023

  

For the year ended December 31, 2022

 
Other income (expense) $2,110,576  $683,253  $160,173  $2,110,576 
Interest income 9,502 111  78,890  9,502 
Interest expense  (613,943)  (791,532)  (331,780)  (613,943)
Total other (expense) $1,506,135 $(108,168) $(92,717) $1,506,135 

  

Other income was $2,110,576$160,173 for 20222023 as compared to other income of $683,253$2,110,576 for 2021. This is an increase in other income of $1,427,323.2022. The increaselarge decrease is primarily due to a $1,797,978 gain on the sale of assets to Pharmalogic Idaho, LLC.LLC in 2022. In February 2022, we entered into an Asset Purchase Agreement with Pharmalogic Idaho, LLC, pursuant to which we sold certain assets for $4,000,000 in cash. The assets consisted primarily of manufacturing equipment and a sublease acquired by the Company in connection with the previously announced termination of the manufacturing and supply agreement with another company.In 2021, we recognized “other income” for an anticipated tax refund of approximately $440,000 for the Employer Retention Credit.

In September 2022, we experienced a fraudulent transactions incident. The fraudulent charges totaled approximately $85,000. These charges were recorded as “other expense”. Investigations by our bank and by law enforcement are ongoing. There have been no indications of any involvement within our Company. As we expected to recoup all fraudulent charges from our bank, we recognized "other income" to offset the fraudulent charges recorded under “other expense”. In October and November 2022, we recovered all the fraudulent charges from our bank.

 

Interest income in 20222023 was $9,502$78,890 as compared to $111$9,502 in 2021.2022. This increase of $9,391$69,388 was due to increased interest rates earned forand increased cash balances held at banks and other institutions in interest-bearing accounts.

 

Interest expense decreased during 2022,2023, to $331,780, from $613,943 from $791,532 in 2021.2022. This decrease of $177,589,$282,163, or approximately 22%46%, was due to a decrease in non-cash interest expense and the payoff of some notes payable.expense. In 2022, non-cash interest expense was $274,443 as compared to $401,077with no comparable expense in 2021. This is a decrease of $126,634.2023. Interest expense includes dividends accrued on our Series C Preferred Stock (as defined below) issued in 2017. In 2022,2023, we recorded interest expense of $243,780 for dividends payable on our Series C Preferred Stock.

 

In connection with the 2013 Promissory Note (as defined below), we recorded $30,000

21

 

In connection with the 2019 Promissory Note (as defined below), we recorded $40,000 of interest expense for 2022 and 2021, and approximately $256,000 of non-cash interest expense related to a debt discount feature and issuance of warrants related to the 2019 Promissory Note for 2022 and 2021. We will have $0 in non-cash interest expense in connection with the 2019 Promissory Note in 2023 and future years.

In connection with our 2017 issuance of Series C Preferred Stock, we issued Class M Warrants and Class N Warrants. All these warrants expired in 2021. We recorded approximately $0 and $131,000 of non-cash interest expense for 2022 and 2021 respectively in relation to these warrants.

Net Income or Loss

 

Our net incomeloss was $303,238$869,016 in 2022,2023, compared to a net loss was $902,347income of $303,238 in 2021.2022. This is an increasea decrease in net income of $1,205,578.$1,172,254. This increasedecrease is largely the result of the approximate $1.8 million gain on sale of assets. Additionally, the increase in income is the result of the increase in revenue in our Radiochemical Products segment offset by the increase in operating expense from salaries and contract labor and expenses from research and developmentassets in 2022 as compared to the same periodwith no such gain in 2021.2023. 

 

Liquidity and Capital Resources

 

On December 31, 2022,2023, we had cash and cash equivalents of $2,375,817$2,688,141 compared to $474,851$2,375,817 at December 31, 2021.2022. Net cash provided by operating activities was $582,589 in 2023, compared to net cash used in operating activities wasof $1,497,719 in 2022, compared to net cash used by operating activities of $161,914 in 2021.2022. This represents an increase in cash used inprovided by operating activities of approximately $1,335,805.$2,080,308. This increase is due to a largeimproved operational performance, decreases in accounts receivable, decreases in Prepaids and current assets, and an increase in accounts receivable due to the increased sales activity in 2022 as compared to 2021payable and decreased net income from operating activitiesaccrued liabilities in the year over year comparison.

 

Accounts receivable at December 31, 20222023 were $1,596,886$1,469,298 as compared to $853,675$1,596,886 at December 31, 2021.2022. Our allowance for bad debt at December 31, 2022 was $0 as compared to $18,9102023 and at December 31, 2021.2022 was $0.

 

Inventories at December 31, 20222023 were $744,793$927,111 as compared to $924,775$744,793 at December 31, 2021. A large portion2022. Part of this increase is due to acquisition of inventory as part of our inventory consistspurchase of Cobalt target inventory. For 2022, our target inventory accounted for approximately 25% of our work in process inventory. For 2021, our target inventory accounted for approximately 48% of our work in process inventory.business assets from AMICI, Inc.

 

Included in our work in process inventory are in-process and completed nuclear medicine products, irradiated cobalt, and nuclear medicine-related materials and products.

 

We recognized a net profitloss of $303,238,$869,016, for the year ended December 31, 2022,2023, and have an accumulated deficit of $126,460,843$127,329,859 since inception. To date, our operations and plant and equipment expenditures have been funded principally from proceeds from public and private sales of debt and equity as well as through asset sales.

 

Net cash used in investing activities was $149,058 for 2023 and net cash provided inby investing activities was $3,879,986 for 20222022. During 2023, we used $149,058 to purchase equipment, and net cash used in investing activities was $205,474 for 2021. During 2022, we used $120,014 to purchase equipment and we used $205,474 to purchase equipment in 2021.2022. We had proceeds from sale of equipment of $4,000,000 in 2022, and we had no proceeds from sale of equipment in 2021.2023.

 

Financing activities usedprovided cash of $472,004$80,504 for the year ended December 31, 2022.2023. We entered into a note payable agreement for $452,100 to finance the purchase of assets. We received proceeds from the sale of common stock in the amount of $8,398 and made principal payment on loans in the amount of $83,389 in 2023. For the year ended December 31, 2022, financing activities used cash of $472,004. We received proceeds from the sale of common stock in the amount of $76,571 and made principal payment on loans in the amount of $540,032 in 2022. For the year ended December 31, 2021, financing activities used cash of $78,699. We received proceeds from the sale of common stock in the amount of $18,890 and issued debt for proceeds of $351,255. In addition, we made principal payment on loans in the amount of $437,627 in 2021.

 

In February 2017, we entered into subscription agreements with certain investors, including two of our directors, for the sale of (i) an aggregate of 3,433 shares of Series C Preferred Stock, and (ii) Class M warrants to purchase an aggregate of 17,165,000 shares of our common stock (Class M Warrants), for gross proceeds of $3,433,000. The Series C Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on February 17th of each year, commencing on February 17, 2018. Shares of Series C Preferred Stock are convertible at the option of the holder at any time into shares of our common stock at an initial conversion price equal to $0.10 per share, subject to adjustment. At any time after February 17, 2019, if the volume-weighted average closing price of our common stock over a period of 90 consecutive trading days is greater than $0.25 per share, we may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per

21 

share plus any accrued and unpaid dividends, payable in shares of common stock. All outstanding shares of Series C Preferred Stock must be redeemed by us on February 17, 2022 at the original purchase price per share, payable in cash or shares of common stock, at the option of the holder. In February 2022, based on approval of majority of the Preferred C Holders, we extended the redemption date of the Series C Preferred Stock to February 17, 2023. In December 2022, based on approval of majority of the Preferred C Holders, we extended the redemption date of the Series C Preferred Stock to February 17, 2025. Holders of Series C Preferred Stock do not have any voting rights, except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock. The Class M Warrants were exercisable at an exercise price of $0.12 per share, subject to adjustment as set forth in the warrant, and expired in February 2022. In February 2022, 515,000 Class M Warrants were exercised at a price of $0.12. The Company received $61,800 for the exercise.

 

In March 2017, we amended our 8% unsecured debentures issued that were scheduled to mature in July 2017 (the Notes) and gave the noteholders certain additional rights (the Amendment). Pursuant to the Amendment, the Notes were modified to provide each holder the right, at the holder’s option and exercisable prior to May 12, 2017, to convert all or any portion of the principal amount of the Notes, plus accrued but unpaid interest, into shares of our Series C Preferred Stock at a conversion price of $1,000 per share. Holders that elected to convert their Notes into Series C Preferred Stock received a warrant to purchase up to 3,750 shares of our common stock for each share of Series C Preferred Stock received upon conversion of the Notes, with each warrant having a five-year term, a cashless exercise feature, and an exercise price of $0.10 per share of common stock. As a result of this modification, an aggregate of $780,000 of the Notes was converted to 780 shares of Series C Preferred Stock and 2,925,000 Class N Warrants. The Class N Warrants (as defined below). Residual interest was also paidwere exercisable at an exercise price of $0.12 per share, subject to Note holders who converted of $1,515. The Notes maturedadjustment as set forth in July 2017the warrant, and were repaidexpired in full.February 2022.

 

As discussed above, in May 2017, we issued 780

In total, 4,213 shares of Series C Preferred Stock and Class N warrants to purchase an aggregatewere issued for gross proceeds of 2,925,000 shares of our common stock (Class N Warrants) upon conversion of $780,000 of the Notes.$4,213,000. The Series C Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on February 17th of each year, commencing on February 17, 2018. Shares of Series C Preferred Stock are convertible at the option of the holder at any time into shares of our common stock at an initial conversion price equal to $0.12$0.10 per share, subject to adjustment. At any time after February 17, 2019, if the volume-weighted average closing price of our common stock over a period of 90 consecutive trading days is greater than $0.25 per share, we may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share plus any accrued and unpaid dividends, payable in shares of common stock.

150 shares of Series C Preferred Stock have previously been converted to common stock at the option of the holder At December 31, 2023, 4,063 shares of Series C Preferred Stock were outstanding. All outstanding shares of Series C Preferred Stock were required to be redeemed by us on February 17, 2022 at the original purchase price per share, payable in cash or shares of common stock, at the option of the holder. In February 2022, based on approval of a majority of the Preferred C Holders, we extended the redemption date of the Series C Preferred Stock to February 17, 2023. In December 2022, based on approval of a majority of the Preferred C Holders, we extended the redemption date of the Series C Preferred Stock to February 17, 2025. Holders of Series C Preferred Stock do not have any voting rights, except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock. The Class N Warrants were exercisable at an exercise price of $0.12 per share, subject to adjustment as set forth in the warrant, and expired in February 2022.

 

In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock.stock based on the average price of the shares over the previous 20 trading days. In connection with the 2013 Promissory Note, each of the two lenders was issued 5,000,000 Class L warrants to purchase shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In June 2014, we renegotiated the terms of the 2013 Promissory Note. Pursuant to the modification, the maturity date was extended to December 31, 2017 and each lender was granted an additional 7,500,000 Class L warrants to purchase shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020, with all remaining terms unchanged. On December 23, 2018, all 25,000,000 Class L warrants expired. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021, with all remaining terms unchanged. In January 2022, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2023, with all remaining terms unchanged. In February 2024, the 2013 Promissory Note was further modified to extend the maturity date to March 31, 2026.

 

In April 2018, we borrowed $120,000 from our then Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an

22 

amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021, and the note was modified to become secured by company assets, with all other provisions remaining unchanged. In December 2021, the 2018 Promissory Note was further modified to extend the maturity date to December 31, 2023, with all remaining terms unchanged. In December 2023, the 2018 Promissory Note was further modified to extend the maturity date to January 31, 2025. In February 2024, the 2018 Promissory Note was further modified to extend the maturity date to March 31, 2026.

 

In December 2019, we entered into a promissory note agreement with our then Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of our major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes us to borrow up to $1,000,000. As of December 31, 2019, we borrowed $675,000 under the 2019 promissory note;Promissory Note; the remaining $325,000 was borrowed in February 2020. The 2019 Promissory Note is secured and bears interest at 4% per annum and has a maturity date of December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, a holder of the 2019 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. In connection with the 2019 Promissory Note, we are required to issue up toissued 30,000,000 Class O Warrants with a term of five years to purchase shares of our common stock at $0.045 per share (the Class O Warrants). The warrants are exercisable at an exercise price of $0.045 per share and have a term of five years.All the Class O Warrants were exercised in January 2021. In December 2022, the 2019 Promissory Note was modified to extend the maturity date to December 31, 2024, with all remaining terms unchanged.

In April 2021, we borrowed $250,000 from its Chief Executive Officer and Chairman ofFebruary 2024, the Board pursuant to a promissory note (the 2021 Promissory Note). The 2021 Promissory Note accrued interest at 6% per annum, which was payable upon maturity of the 2021 Promissory Note. The 20212019 Promissory Note was originally secured and wasfurther modified to mature on December 31, 2022. At any time,extend the holders of the 2021 Promissory Note were ablematurity date to elect to have any or all of the principal and accrued interest settled with shares of our common stock at a conversion price of $0.11 per share. On March 31, 2022, the Company repaid the 2021 Promissory Note in full. The payment included $250,000 in principal and $14,500 in interest.2026.

 

We expect that cash from operations, cash obtained through securities offerings, and our current cash balance will be sufficient to fund operations for the next twelve months. Although we may seek additional debt financing for our projects and operations in the future, there is no assurance that we will be able to secure additional debt financing on acceptable terms to us, or at all.

 

Goals for 20232024

 

Based upon the investments we have made in our facilities and investments we anticipate making, and based on projects, and products developed thus far in 2023, we have the following goals for the rest of 2023:2024:

 

·

Continue to expand sales of our FDA approved sodium iodide I-131 generic drug product;product, including entering new territories;

 

·

Complete development of and launch a fully automated I-131 capsule loading system to pharmacies in the U.S and select overseas customers;

 

·

Begin development of one or more new generic drug

Launch our Medical Devices business segment beginning by offering products to further enhance revenue production within our Radiochemical segment and identify additional future generic product opportunities;purchased from AMICI, Inc. in 2023.

 

·

Expand sales of our nuclear medicine products and increase cash flow by offering new products and further expanding our international sales and distributor relationships;

 

·

Develop a business plan to produce additional radiopharmaceutical products or explore new contract manufacturing opportunities.

·Explore acquisition opportunities to expand our product offerings and increase, revenue, cash flow, and profit margin;  

 

·

Continue to expand our customer base, increase revenues, reduce production and operating costs, and attempt to achieve profitability in our core business segment operations; and

 

·

Continue to support essential tasks related to our de-conversion project and continue to pursue any opportunities to benefit from sale of these assets through and through royalty payment arrangements.efforts towards closing the DUF6 Asset Sale agreement.

23 

 

Critical Accounting Estimates

Asset retirement obligation– The asset retirement obligation is based on the expected future cash flows of the decommissioning funding plan. The decommissioning funding plan is based on the estimated number of hours of specific personnel, estimated wages and disposal costs. Once the decommissioning funding plan has been developed, we use a discount rate to determine the estimated current value of the liability.

 

Item 7A.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company, and therefore, are not required to provide the information required by this item.

 

Item 8.       FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The following financial statements are included herewith and are hereby incorporated by reference:

 

Index to Consolidated Financial Statements

 

 

Page No.

Report of Independent Registered Public Accounting Firm

F-1

Financial Statements:

 

Consolidated Balance Sheets as of December 31, 20222023 and 20212022

F-2

F-3

Consolidated Statements of Operations for the years ended December 31, 20222023 and 20212022

F-3

F-4

Consolidated Statement of Shareholders’ Equity for the years ended December 31, 20222023 and 20212022

F-4

F-5

Consolidated Statements of Cash Flows for the years ended December 31, 20222023 and 20212022

F-5

F-6

Notes to Consolidated Financial Statements

F-6

F-7

 

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

Item 9A.    CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rules 13a-15I and 15d-15(e) under the Exchange Act) that are designed to ensure information required to be disclosed in our reports that are filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Management, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), has conducted an evaluation (pursuant to Rule 13a-15(b) of the Exchange Act) of the effectiveness of our disclosure controls and procedures as of December 31, 2022.2023. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of December 31, 2022.2023.

 

 

Management’sManagements Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act). Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the U.S. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures are made in accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.

 

Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria established in Internal Control — Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation. Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2022.2023.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the yearthree months ended December 31, 2022,2023, that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

 

Item 9B.      OTHER INFORMATION

 

None.During the quarter ended December 31, 2023, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

Item 9C.      DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

None.

 

PART III.

 

Item 10.      DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

 

We have adopted a Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer and controller, or persons performing similar functions. Our Code of Ethics is posted on our website and can be accessed, free of charge, at http://www.intisoid.com. If we waive, or implicitly waive, any material provision of the Code of Ethics that apply to our executive officers, or substantively amend the Code of Ethics, in each case that is required to be disclosed, we will disclose that fact on our website.

 

The other information required by this item is incorporated by reference from our definitive proxy statement for our 20232024 annual meeting of shareholders, which will be filed with the SEC within 120 days after December 31, 2022.2023.

 

Item 11.      EXECUTIVE COMPENSATION

 

The information required by this item is incorporated by reference from our definitive proxy statement for our 20232024 annual meeting of shareholders, which will be filed with the SEC within 120 days after December 31, 2022.2023.

 

Item 12.      SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The information required by this item is incorporated by reference from our definitive proxy statement for our 20232024 annual meeting of shareholders, which will be filed with the SEC within 120 days after December 31, 2022.

25 2023.

 

 

Item 13.      CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by this item is incorporated by reference from our definitive proxy statement for our 20232024 annual meeting of shareholders, which will be filed with the SEC within 120 days after December 31, 2022.2023.

Item 14.      PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The information required by this item is incorporated by reference to our definitive proxy statement for our 20232024 annual meeting of shareholders, which will be filed with the SEC within 120 days after December 31, 2022.2023.

 

Item 15.      EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

(a)(1)and (a)(2)Financial Statements

See the index to and the financial statements beginning on page [31], which financial statements are incorporated herein by reference.

 

(a)(3) Exhibits

The following documents are filed or incorporated herein by reference as exhibits to this report:

 

2.1++

2.1++Membership Interest Purchase Agreement, dated July 8, 2021, between RadQual, LLC, International Isotopes Inc., and each of the sellers named therein (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on July 14, 2021).

2.2++Asset Purchase Agreement, dated February 10, 2022, between International Isotopes Inc. and Pharmalogic Idaho, LLC (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on February 16, 2022).

 

2.2++

Asset Purchased Agreement, dated February 8, 2024, among International Isotopes Inc., International Isotopes Fluorine Products, Inc. and American Fuel Resources, LLC (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on February 8, 2024).#

3.1

Restated Certificate of Formation of the Company, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q for quarter ended June 30, 2010).

 

3.2

3.2

Statement of Designation of the Series C Convertible Redeemable Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on February 24, 2017).

 

3.3

3.3

Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock of International Isotopes Inc., dated February 16, 2022 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on February 22, 2022).

 

3.4

3.4

Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock of International Isotopes Inc., dated December 28, 2022 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed December 28, 2022).

 

3.5

3.5

Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Company’s Registration Statement on Form SB-2 filed on May 1, 1997 (Registration No. 333-26269).

 

10.1†

10.1†

International Isotopes Inc. Amended and Restated Employee Stock Purchase Plan (incorporated by reference to Exhibit 10,110.1 of the Company’s Current Report on Form 8-K, filed on July 21, 2020).

 

10.2†

10.2†

International Isotopes Inc. Amended and Restated 2015 Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed on July 30, 2018).

 

10.3+

10.3+

Lease Agreement (4137 Commerce Circle), dated January 20, 2020, between the Company and Adrian Rand Robison and Dorothy RobisonRobison..

 

10.4†

10.4†

Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K filed on September 17, 2008).

 

 

10.5

10.5

Memorandum of Agreement, dated October 22, 2009, between the Company and the New Mexico Environment Department (incorporated by reference to Exhibit 99.1 of the Company’s Current Report on Form 8-K filed on October 27, 2009).

 

10.6

10.6

Registration Rights Agreement, dated February 17, 2017, among the Company and the purchasers named therein (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on February 24, 2017).

 

10.7†

Amended and RestatedExecutive Employment Agreement, dated May 16, 2012,December 23, 2022, between the Company and Stephen Laflin (incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012).

10.8†

Modification #3 to the Amended and Restated Employment Agreement, dated February 22, 2023, between the Company and Stephen LaflinShahe Bagerdjian (as amended) (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed on February 28,May 8, 2023).

 

10.8

10.9

Promissory Note Agreement, dated December 23, 2013, among the Company, Ralph Richart and John McCormack (incorporated by reference to Exhibit 10.19 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013).

 

10.9

10.10

Modification #1 to the Promissory Note Agreement, dated June 30, 2014, among the Company, Ralph M. Richart and John M. McCormack (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014).

 

10.10

10.11Modification #2 to the Promissory Note Agreement, dated February 3, 2017, among the Company, Ralph M. Richart and John M. McCormack (incorporated by reference to Exhibit 10.18 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016).

10.12Isotope and Technical Service Order Form, dated October 2, 2014, between the Company and the U.S. Department of Energy (incorporated by reference to Exhibit 10.18 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014).**

21.1+

Subsidiary list.

 

23.1+

10.13Cobalt-60 Pellet Supply Agreement, dated April 7, 2015, between Nordion (Canada) Inc., as general partner of and on behalf of Nordion Sterilization LP, and International Isotopes Inc. (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015).**

10.14First Modification to Cobalt-60 Pellet Supply Agreement, effective April 21, 2017, between International Isotopes Inc. and Nordion (Canada) Inc., as general partner of and on behalf of Nordion Sterilization LP (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on May 10, 2017).**

10.15Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock International Isotopes Inc (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on December 28, 2022).

27 

21.1+Subsidiary list.

23.1+Consent of Haynie & Company.

 

31.1+

31.1+

Certification of Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2+

31.2+

Certification of Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1*

32.1*

Certification of Chief Executive Officer furnished under Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2*

32.2*

Certification of Chief Financial Officer furnished under Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS+

101.INS+

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH+

101.SCH+

Inline XBRL Taxonomy Extension Schema Document

101.CAL+

101.CAL+

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF+

101.DEF+

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB+

101.LAB+

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE+

101.PRE+

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

104

Cover Page Interactive Data File (embedded within the(formatted as Inline XBRL document and contained in Exhibit 101101)

 

† This exhibit constitutes a management contract or compensatory plan or arrangement.

 

** Confidential treatment has been granted as to certain portions, which portions were omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.

++ Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to supplementally furnish copies of any omitted schedules to the Securities and Exchange Commission upon request.

#  Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is not material and is the type of information that the registrant treats as private or confidential.

+ Filed herewith.

 

* Furnished herewith.

 

 

Item 16.      FORM 10-K SUMMARY

 

None.

 

 

29 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

International Isotopes Inc.

  
  
 

By:  /s/ Steve T. LaflinShahe Bagerdjian

 Steve T. Laflin

Shahe Bagerdjian

 

President, Chief Executive Officer, and Director

  
 

Date:  April 5, 2023March 28, 2024

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

April 5, 2023

March 28, 2024

By:  /s/ Steve T. LaflinShahe Bagerdjian

 Steve T. Laflin

Shahe Bagerdjian

 

President, Chief Executive Officer, and Director

 

April 5, 2023

March 28, 2024

By:  /s/ W. Matthew Cox

 

W. Matthew Cox

 

Chief Financial Officer, Secretary

 

April 5, 2023

March 28, 2024

By:  /s/ Robert Atcher

 

Robert Atcher

 

Director

 

April 5, 2023

March 28, 2024

By:  /s/ Christopher Grosso

 

Christopher Grosso

 

Chairman of the Board of Directors

 

March 28, 2024

By:  /s/ Steve Laflin

Steve Laflin

Director

 

30 

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

 

CONSOLIDATED FINANCIAL STATEMENTS

 

TABLE OF CONTENTS

 

 

Page No.

Report of Independent Registered Public Accounting Firm (PCAOB(Haynie & Company, Salt Lake City, UT, PCAOB ID No. 457)457)

F-1

Financial Statements:

 

Consolidated Balance Sheets as of December 31, 20222023 and 20212022

F-3

Consolidated Statements of Operations for the years ended December 31, 20222023 and 20212022

F-4

Consolidated Statement of Shareholders’ Equity for the years ended December 31, 20222023 and 20212022

F-5

Consolidated Statements of Cash Flows for the years ended December 31, 20222023 and 20212022

F-6

Notes to Consolidated Financial Statements

F-7

 

 

auditopinionjpg_page1.jpg

 

auditopinionjpg_page2.jpg

 

F-1 

Haynie & Company

Salt Lake City, Utah

 F-2

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Consolidated Balance Sheets

 

 December 31, December 31,  

December 31,

 

December 31,

 
 2022 2021  

2023

  

2022

 
Assets          
      
Current assets         
Cash and cash equivalents $2,375,817  $474,851  $2,688,141  $2,375,817 
Accounts receivable  1,596,886   853,675  1,469,298  1,596,886 
Inventories  744,793   924,775  927,111  744,793 
Prepaids and other current assets  1,023,129   1,004,423   672,934   1,023,129 
Total current assets  5,740,625   3,257,724   5,757,484   5,740,625 
         
Long-term assets         
Restricted cash  840,049   830,752  880,752  840,049 
Property, plant and equipment, net  2,024,486   4,299,937  2,465,077  2,024,486 
Capitalized lease disposal costs, net  228,125   246,748  688,462  228,125 
Financing lease right-of-use asset  12,621   18,631  6,611  12,621 
Operating lease right-of-use asset  2,311,082   2,429,622  2,183,988  2,311,082 
Goodwill  1,384,255   1,384,255  1,384,255  1,384,255 
Patents and other intangibles, net  3,703,353   3,859,473   3,538,458   3,703,353 
Total long-term assets  10,503,971   13,069,418   11,147,603   10,503,971 
Total assets $16,244,596  $16,327,142  $16,905,087  $16,244,596 
         
Liabilities and Stockholders' Equity             
Current liabilities         
Accounts payable $382,392  $1,424,028   559,597  $382,392 
Accrued liabilities  1,472,504   1,189,165  1,482,179  1,472,504 
Unearned revenue  879,365   907,953  932,682  879,365 
Current portion of operating lease right-of-use liability  131,572   121,069  140,733  131,572 
Current portion of financing lease liability  5,513   8,542  2,832  5,513 
Current portion of related party notes payable, net of debt discount  620,000   993,735    620,000 
Current installments of notes payable  23,348   290,017   155,733   23,348 
Total current liabilities  3,514,694   4,934,509   3,273,756   3,514,694 
         
Long-term liabilities         
Accrued long-term liabilities  112,500       75,000  112,500 
Related party notes payable, net of current portion and debt discount  1,000,000   620,000  1,620,000  1,000,000 
Notes payable, net of current portion  34,406   57,769  270,732  34,406 
Asset retirement obligation  942,378   892,086  1,474,463  942,378 
Financing lease liability, net of current portion  2,832   8,346    2,832 
Operating lease right-of-use liability, net of current portion  2,232,244   2,363,815  2,091,511  2,232,244 
Mandatorily redeemable convertible preferred stock, net of current portion and discount  4,063,000   4,719,822 

Mandatorily redeemable convertible preferred stock

  4,063,000   4,063,000 
Total long-term liabilities  8,387,360   8,661,838   9,594,706   8,387,360 
Total liabilities  11,902,054   13,596,347   12,868,462   11,902,054 
         
Stockholders' equity         
Common stock, $0.01 par value; 750,000,000 shares authorized; 514,889,916 and 502,584,176 shares issued and outstanding respectively  5,148,899   5,025,842 

Common stock, $0.01 par value; 750,000,000 shares authorized; 519,787,870 and 514,889,916 shares issued and outstanding respectively

 5,197,879  5,148,899 
Additional paid in capital  125,654,486   124,469,034  126,168,605  125,654,486 
Accumulated deficit  (126,460,843)  (126,764,081)  (127,329,859)  (126,460,843)
Total equity  4,342,542   2,730,795   4,036,625   4,342,542 
Total liabilities and stockholders' equity $16,244,596  $16,327,142  $16,905,087  $16,244,596 

 

See accompanying notes to consolidated financial statements.

 

F-3 

F-3

 

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Consolidated Statements of Operations

 

         
  Years ended December 31, 
  2022  2021 
       
Sale of product $11,181,988  $9,661,942 
Cost of product  4,891,927   3,924,142 
Gross profit  6,290,061   5,737,800 
         
Operating costs and expenses:        
Salaries and contract labor  3,390,652   2,687,735 
General, administrative and consulting  3,568,590   3,459,143 
Research and development  533,716   271,714 
Total operating expenses  7,492,958   6,418,592 
         
Operating loss  (1,202,897)  (680,792)
         
Other income (expense):        
Other income  2,110,576   683,253 
Interest income  9,502   111 
Interest expense  (613,943)  (791,532)
Total other (expense) income  1,506,135   (108,168)
Net income (loss)  303,238   (788,960)
Income attributable to noncontrolling interest       113,387 
         
Net income (loss) attributable to International Isotopes Inc. $303,238  $(902,347)
         
Net income per common share - basic: $    $   
         
Net income per common share - diluted: $    $   
         
Weighted average common shares outstanding - basic  510,794,145   477,723,996 
         
Weighted average common shares outstanding - diluted  510,794,145   477,723,996 

See accompanying notes to consolidated financial statements.

F-4 

  

Years ended December 31,

 
  

2023

  

2022

 
         

Sale of product

 $12,267,385  $11,181,988 

Cost of product

  4,888,409   4,891,927 

Gross profit

  7,378,976   6,290,061 
         

Operating costs and expenses:

        

Salaries and contract labor

  4,032,155   3,390,652 

General, administrative and consulting

  3,545,766   3,568,590 

Research and development

  577,354   533,716 

Total operating expenses

  8,155,275   7,492,958 
         

Operating loss

  (776,299)  (1,202,897)
         

Other income (expense):

        

Other income

  160,173   2,110,576 

Interest income

  78,890   9,502 

Interest expense

  (331,780)  (613,943)

Total other (expense) income

  (92,717)  1,506,135 

Net income (loss)

 $(869,016) $303,238 
         

Net income per common share - basic:

 $  $ 
         

Net income per common share - diluted:

 $  $ 
         

Weighted average common shares outstanding - basic

  517,777,847   510,794,145 
         

Weighted average common shares outstanding - diluted

  517,777,847   510,794,145 

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Consolidated Statement of Stockholders' Equity

Years ended December 31, 2022 and 2021

              Equity       
              Attributable  Equity    
              to  Attributable    
        Additional     Internat'l  to    
  Common Stock  Paid-in  Accumulated  Isotopes  Noncontrolling  Total 
  Shares  Amount  Capital  Deficit  Shareholders  Interest  Equity 
Balance December 31, 2020  424,344,298  $4,243,443  $122,191,837  $(125,861,734) $573,546  $2,313,706  $2,887,252 
                             
Shares issued under employee stock purchase plan  313,420   3,135   15,753        18,888        18,888 
                              
Shares issued for exercise of employee stock options  2,024,798   20,248   (20,248)                    
                              
Stock grant  118,315   1,183   (1,183)                    
                              
Stock issued in lieu of dividends on preferred C shares  1,398,200   13,982   193,498        207,480        207,480 
                              
Warrant exercise  32,621,409   326,214   (326,214)                    
                              
Conversion of preferred C stock  1,500,000   15,000   135,000        150,000        150,000 
                              
Conversion of preferred B stock  87,500   875   174,125        175,000        175,000 
                              
Stock based compensation  —          84,566        84,566        84,566 
                              
Shares issued for purchase of 75.5% of RadQual  40,176,236   401,762   2,021,900       2,423,662   (2,423,662)     
                              
Distribution to non-controlling interest  —                         (3,431)  (3,431)
                              
Net (loss) income              (902,347)  (902,347)  113,387   (788,960)
Balance December 31, 2021  502,584,176   5,025,842   124,469,034   (126,764,081)  2,730,795        2,730,795 
                             
Shares issued under employee stock purchase plan  245,081   2,451   12,320        14,771        14,771 
                              
Shares issued for exercise of employee stock options  648,948   6,489   (6,489)                    
                              
Stock grant  187,231   1,872   (1,872)                    
                              
Stock issued in lieu of dividends on preferred C shares  2,271,980   22,720   181,760        204,480        204,480 
                              
Warrant exercise  515,000   5,150   56,650        61,800        61,800 
                              
Conversion of preferred B stock  8,437,500   84,375   590,625        675,000        675,000 
                              
Stock based compensation  —          352,458        352,458        352,458 
                              
Net (loss) income              303,238   303,238        303,238 
Balance December 31, 2022  514,889,916  $5,148,899  $125,654,486  $(126,460,843) $4,342,542  $    $4,342,542 

Common Stock

Additional Paid-in Capital

Accumulated Deficit

Equity Attributable to Internat’l Isotopes Shareholders

Equity Attributable to Noncontrolling Interest

F-5 

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

         
  Years ended December 31, 
  2022  2021 
Cash flows from operating activities:        
Net income (loss) $303,238  $(788,960)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:        
Depreciation and amortization  374,196   581,274 
Gain on disposal of property, plant and equipment  (1,797,978)     
Accretion of obligation for lease disposal costs  50,292   43,266 
Accretion of beneficial conversion feature  274,443   401,077 
Equity based compensation  352,458   84,564 
Right-of-use amortization  (2,528)  23,989 
Changes in operating assets and liabilities:        
Accounts receivable  (743,211)  (57,547)
Prepaids and other current assets  (18,706)  243,007 
Inventories  179,982   (86,988)
Unearned revenues  (28,588)  (106,249)
Accounts payable and accrued liabilities  (441,317)  (499,347)
Net cash used in operating activities  (1,497,719)  (161,914)
         
Cash flows from investing activities:        
Proceeds from sale of property, plant and equipment  4,000,000      
Purchase of property, plant, equipment and patents  (120,014)  (205,474)
Net cash provided by (used in) investing activities  3,879,986   (205,474)
         
Cash flows from financing activities:        
Proceeds from sale of stock  76,571   18,890 
Proceeds from issuance of notes payable       101,253 
Proceeds from issuance of debt - related party       250,000 
Distribution to non-controlling interest       (3,431)
Payments on financing lease liability  (8,543)  (7,786)
Principal payments on notes payable  (540,032)  (437,627)
Net cash used in financing activities  (472,004)  (78,701)
         
Net change in cash and cash equivalents  1,910,263   (446,089)
Cash and cash equivalents at beginning of year  1,305,603   1,751,692 
Cash and cash equivalents at end of year $3,215,866  $1,305,603 
         
Supplemental disclosure of cash flow activities:        
Cash paid for interest $54,071  $75,786 
         
Supplemental disclosure of noncash financing and investing transactions:        
Decrease in accrued interest and increase in equity for conversion preferred dividends to stock $204,480  $207,480 
Increase in operating lease right-of-use asset and right-of-use liability for new lease $    $1,603 
Increase in equity and decrease in liability for the conversion of preferred stock $675,000  $325,000 
Non-cash increase of capitalized asset retirement obligation for increased funding plan $    $260,715 
Decrease in unearned revenue and increase in notes payable for repayment plan $    $146,072 
Increase in equity and decrease in non-controlling interest for acquisition of non-controlling interest in RadQual and TI Services $    $2,423,662 

  December 31, 
  2022  2021 
Cash and cash equivalents $2,375,817  $474,851 
Restricted cash included in long-term assets  840,049   830,752 
Total cash, cash equivalents, and restricted cash shown in statement of cash flows $3,215,866  $1,305,603 

 

See accompanying notes to consolidated financial statements.

 

F-6 

F-4

 

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Consolidated Statement of Stockholders' Equity

Years ended December 31, 2023 and 2022

  

Common Stock

  

Additional Paid-in

  

Accumulated

  

Total

 
  

Shares

  

Amount

  

Capital

  

Deficit

  

Equity

 

Balance December 31, 2021

  502,584,176  $5,025,842  $124,469,034  $(126,764,081) $2,730,795 
                     

Shares issued under employee stock purchase plan

  245,081   2,451   12,320      14,771 
                     

Shares issued for exercise of employee stock options

  648,948   6,489   (6,489)      
                     

Stock grant

  187,231   1,872   (1,872)      
                     

Stock issued in lieu of dividends on preferred C shares

  2,271,980   22,720   181,760      204,480 
                     

Warrant exercise

  515,000   5,150   56,650      61,800 
                     

Conversion of preferred B stock

  8,437,500   84,375   590,625      675,000 
                     

Stock based compensation

        352,458      352,458 
                     

Net income

              303,238   303,238 

Balance December 31, 2022

  514,889,916   5,148,899   125,654,486   (126,460,843)  4,342,542 
                     

Shares issued under employee stock purchase plan

  316,866   3,169   5,229      8,398 
                     

Shares issued for exercise of employee stock options

               
                     

Stock grant

  343,560   3,436   (3,436)      
                     

Stock issued in lieu of dividends on preferred C shares

  2,266,500   22,665   67,995      90,660 
                     

Shares issued for issuance of RSUs

  1,971,028   19,710   (19,710)      
                     

Stock based compensation

  -   -   464,041      464,041 
                     

Net loss

              (869,016)  (869,016)

Balance December 31, 2023

  519,787,870  $5,197,879  $126,168,605  $(127,329,859) $4,036,625 

See accompanying notes to consolidated financial statements.

F-5

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

  

Years ended December 31,

 
  

2023

  

2022

 

Cash flows from operating activities:

        

Net (loss) income

 $(869,016) $303,238 

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

        

Depreciation and amortization

  350,094   374,196 

Gain on disposal of property, plant and equipment

     (1,797,978)

Accretion of obligation for lease disposal costs

  53,126   50,292 

Accretion of beneficial conversion feature

     274,443 

Equity based compensation

  464,041   352,458 

Right-of-use amortization

  (4,478)  (2,528)

Changes in operating assets and liabilities:

        

Accounts receivable

  127,588   (743,211)

Prepaids and other current assets

  350,195   (18,706)

Inventories

  (182,318)  179,982 

Accounts payable and accrued liabilities

  240,040   (441,317)

Unearned revenues

  53,317   (28,588)

Net cash provided by (used in) in operating activities

  582,589   (1,497,719)
         

Cash flows from investing activities:

        

Proceeds from sale of property, plant and equipment

     4,000,000 

Purchase of property, plant, equipment and patents

  (149,058)  (120,014)

Net cash (used in) provided by investing activities

  (149,058)  3,879,986 
         

Cash flows from financing activities:

        

Proceeds from sale of stock

  8,398   76,571 

Payments on financing lease liability

  (5,513)  (8,543)

Principal payments on notes payable

  (83,389)  (540,032)

Net cash provided by (used in) financing activities

  (80,504)  (472,004)
         

Net increase in cash and cash equivalents and restricted cash

  353,027   1,910,263 

Cash and cash equivalents and restricted cash at beginning of year

  3,215,866   1,305,603 

Cash and cash equivalents and restricted cash at end of year

 $3,568,893  $3,215,866 
         

Supplemental disclosure of cash flow activities:

        

Cash paid for interest

 $163,920  $54,071 

Cash paid for taxes

  10,176   9,097 
         

Supplemental disclosure of noncash financing and investing transactions:

        

Decrease in accrued interest and increase in equity for conversion preferred dividends to stock

 $90,660  $204,480 

Increase in equity and decrease in liability for the conversion of preferred stock

 $  $675,000 

Property acquired in exchange for a note payable

 $452,100  $ 

Non-cash increase of capitalized asset retirement obligation for increased funding plan

 $478,959  $ 

  

December 31,

 
  

2023

  

2022

 

Cash and cash equivalents

 $2,688,141  $2,375,817 

Restricted cash included in long-term assets

  880,752   840,049 

Total cash, cash equivalents, and restricted cash shown in statement of cash flows

 $3,568,893  $3,215,866 

See accompanying notes to consolidated financial statements.

F-6

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED December 31, 20222023 AND 20212022

 

NOTE 1 – DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

 

Description of business – International Isotopes Inc. (the “Company” or “INIS”) was incorporated in Texas in November 1995. The accompanying consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include all operations and balances of the Company and its wholly-owned subsidiaries, International Isotopes Idaho Inc., International Isotopes Fluorine Products, Inc., and International Isotopes Transportation Services, Inc. The consolidated financial statements also include the accounts of wholly owned subsidiaries TI Services, LLC, (“TI Services”), and RadQual, LLC (RadQual). TI Services is headquartered in Youngstown, Ohio and was formed with RadQual in December 2010 to distribute products and services for nuclear medicine, nuclear cardiology and Positron Emission Tomography (PET) imaging. RadQual is a global supplier of molecular imaging quality control devices, and is now headquartered in Idaho Falls, Idaho. In addition, the Company had a 24.5% interest in RadQual. In August 2017, affiliates of the Company purchased the remaining 75.5% of RadQual and at the time the Company was named as one of the two managing members of RadQual. As a result of this ownership change, the Company has significant influence in management decisions with regard to RadQual’s business operations. In July 2021, the Company purchased the remaining 75.5% of RadQual. RadQual and TI Services are now wholly-owned subsidiaries of the Company.

Affiliates 

Nature of Operations – INIS and its subsidiaries, (collectively, the “Company,” “we,” “our” or “us”) manufacture a full range of nuclear medicine calibration and reference standards, a wide range of products, including cobalt teletherapy sources, and a varied selection of radioisotopes and radiochemicals for medical research, pharmacy compounding, and clinical applications. The Company also distributes a varied selection of radioisotopes and radiochemicals for medical and clinical research applications.an FDA-approved radiopharmaceutical drug product. The Company also holds several patents for a fluorine extraction process that it plans to usewould be used in conjunction with a proposed commercial depleted uranium de-conversion facility which would be located in Lea County, New Mexico (the “De-Conversion Facility”). The Company’s business consists of four major business segments: Theranostics Products (formerly Radiochemical Products), Cobalt Products, Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Fluorine Products. The Company’s headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.

 

With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than the operating cycle, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under current or long-term liabilities on the Company’s consolidated balance sheets. These unearned revenues will be recognized as revenue in the future period during whichwhen the cobalt shipments begin.shipment takes place. All assets expected to be realized in cash or sold during the normal operating cycle of the business are classified as current assets.

 

Principles of Consolidation– The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including RadQual and TI Services. All significant intercompany accounts and transactions have been eliminated during consolidation.

 

Significant accounting policies

 

a)Financial instruments and cash equivalents

 

The carrying value of notes payable approximates fair value because they bear interest at rates which approximate market rates.

 

Cash and cash equivalents, totaling $2,375,817$2,688,141 and $474,851$2,375,817 at December 31, 20222023 and 2021,2022, respectively, consist of operating accounts and money market accounts. For purposes of the consolidated statements of cash flows, the Company considers all highly-liquid financial instruments with original maturities of three months or less at date of purchase to be cash equivalents.

 

At December 31, 20222023 and 2021,2022, the Company had pledged cash on deposit in a money market account valued at $840,049$880,752 and $830,752$840,049 respectively, as security for a surety bond.  The surety bond is required as part of the Company’s operating license agreement with the Nuclear Regulatory Commission (“NRC”).

 

The Company maintains its cash accounts in various deposit accounts, the balances of which are periodically in excess of federally insured limits.

 

F-7 
F- 7

b)Accounts receivable

 

The Company sells products mainly to recurring customers, wherein the customer’s ability to pay has previously been evaluated. The Company generally does not require collateral. The Company periodically reviews accounts receivable for amounts considered uncollectible and allowances are provided for uncollectible accounts when deemed necessary. At December 31, 2023 and December 31, 2022 the Company had no allowance for doubtful accounts. At December 31, 2021, the Company has accrued an allowance for doubtful accounts of approximately $19,000.

 

c)Inventories

 

Inventories are carried at the lower of cost or net realizable value. Cost is determined using the first in, first out method. When indicators of inventory impairment exist, the Company measures the carrying value of the inventory against its market value, and if the carrying value exceeds the market value, the inventory value is adjusted down accordingly.  No impairment was recorded for the years ended December 31, 2023 and December 31, 2022 and December 31, 2021..

 

d)Property, plant and equipment

 

Depreciation on property, plant and equipment is computed using the straight-line method over the estimated useful life of the asset.

 

Leasehold improvements are amortized over the shorter of the life of the lease or the service life of the improvements. Maintenance, repairs, and renewals that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred. Gains or losses on dispositions of property and equipment are included in the results of operations.

 

e)Goodwill and other intangibles

 

Goodwill is not amortized but is tested for impairment at least annually. Goodwill represents the excess of the purchase price over the fair value of net tangible and identifiable intangible assets recorded as a result of the change in ownership of RadQual. As of December 31, 20222023 and 2021,2022, there has been no impairment of goodwill.

 

Patents and other intangibles are amortized using the straight-line method over their estimated useful lives and are evaluated for impairment at least annually or when events or circumstances arise that indicate the existence of impairment. The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include but are not limited to: (1)(1) a significant decrease in the market value of an asset, (2)(2) a significant adverse change in the extent or manner in which an asset is used, or (3)(3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. When indicators of impairment exist, the Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. During the years ended December 31, 20222023 and 2021,2022, the Company had no impairment losses related to intangible assets.

 

f)Impairment of long-lived assets

 

Long-lived assets are reviewed for impairment annually, or when events or circumstances arise that indicate the existence of impairment, using the same evaluation process as described above for patents and other intangibles.  There was no impairment recorded during the years ended December 31, 20222023 and 2021.2022.

 

g)Income taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in income in the period that includes the enactment date.

 

F-8 

F- 8

h)Use of estimates

 

Management of the Company has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period to prepare these consolidated financial statements in conformity with GAAP.  Actual results could differ from those estimates.

 

i)Revenue recognition

 

Revenue is recognized when products are shipped. No warranty coverage or right of return provisions are provided to customers. Amounts received as prepayment on future products or services are recorded as unearned revenues and recognized as income when the product is shipped or service performed. See Note 14 Revenue Recognition.

 

j)      Advertising Expenses

Advertising expenses, which include promotional expenses, are expensed as incurred and totaled $142,188 and $118,465 for the years ended December 31, 2023 and 2022, respectively.

k)      Research and development costs

 

Research and development costs are expensed as incurred and totaled $533,716$577,354 and $271,714$533,716 for the years ended December 31, 20222023 and 2021,2022, respectively. These research and development costs were incurred to maintain our planned de-conversion facility licensefor corporate business development and in our radiochemical productsTheranostics Products and nuclear medicine standardsNuclear Medicine Standards business segments.

 

k)

l)      Share-based compensation

 

The Company accounts for issuances of share-based compensation to employees in accordance with GAAP which requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements and is measured based on the grant date fair value of the award. Compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

 

For the years ended December 31, 20222023 and 2021,2022, the Company recognized share-based compensation expense of $352,458$464,041 and $84,564,$352,458, respectively, related to stock options, stock grants, and restricted stock grants.units. This expense is included as part of salaries and contract labor in the accompanying statements of operations.

 

l)

m)      Net loss per common share – basic and diluted

 

Basic loss per share is computed on the basis of the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed on the basis of the weighted-average number of common shares plus all potentially dilutive issuable common shares outstanding during the year.

 

The table below shows the calculation of diluted shares:

Description of Business and Significant Accounting Policies - Schedule of Weighted Average Number of Shares

     
 December 31,  

December 31,

 
 2022 2021  

2023

  

2022

 
Weighted average common shares outstanding - basic  510,794,145   477,723,996  517,777,847  510,794,145 
         
Effects of dilutive shares         
Stock options  —     —       
Warrants  —     —   
Series B redeemable convertible preferred stock Series B Redeemable Convertible Preferred Stock  —     —   
Series C redeemable convertible preferred stock Series C Redeemable Convertible Preferred Stock  —     —   

Series C redeemable convertible preferred stock

   
Weighted average common shares outstanding - diluted  510,794,145   477,723,996   517,777,847   510,794,145 

 

For the year ended December 31, 2022,2023, the Company had 24,993,50024,787,500 stock options outstanding, and 4,063 outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), each of which were not included in the computation of diluted income per common share because they would be anti-dilutive.

 

For the year ended December 31, 2021,2022, the Company had 20,777,50024,993,500 stock options outstanding, 7,065,000 warrants outstanding, and 4,063 outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), and 675 outstanding shares of Series B redeemable convertible preferred stock (Series B Preferred Stock), each of which were not included in the computation of diluted income per common share because they would be anti-dilutive.

 

F-9 

F- 9

The table below summarizes common stock equivalents outstanding at December 31, 20222023 and 2021:2022:

Description of Business and Significant Accounting Policies - Schedule of Common Stock Equivalents Outstanding

         
  December 31, 
  2022  2021 
Stock options  24,993,500   20,777,500 
Warrants       7,065,000 
850 Shares of Series B redeemable convertible preferred stock  —     337,500 
4,213 Shares of Series C redeemable convertible preferred stock  40,630,000   40,630,000 
   65,623,500   68,810,000 
  

December 31,

 
  

2023

  

2022

 

Stock options

  24,787,500   24,993,500 

4,063 Shares of Series C redeemable convertible preferred stock

  40,630,000   40,630,000 
   65,417,500   65,623,500 

 

m)

n)      Business segments and related information

 

GAAP establishes standards for the way public business enterprises are to report information about operating segments in annual financial statements and requires enterprises to report selected information about operating segments in interim financial reports issued to shareholders. It also establishes standards for related disclosure about products and services, geographic areas and major customers. The Company currently operates in four business segments.

 

n)

o)      Recent accounting standards

 

In August 2020, the Financial Accounting Standards Board issued ASU 2020-062020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20)470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)815-40). The update simplifies accounting related to convertible debt instruments. The standard is effective for fiscal years beginning after December 15, 2023 including interim periods within those fiscal years. INIS is currently evaluating the effect this standard will have on its financial statements.

NOTE 2 – BUSINESS CONDITION AND LIQUIDITY

 

The Company has a history of recurring losses with an accumulated deficit of $126,460,843$127,329,859 at December 31, 20222023 and net incomeloss of $303,238$869,016 for the year then ended. The Company’s working capital which includes inventory that will not be sold for up to three years, has increased by $3,902,716$257,797 from the prior year. The Company has cash flows usedprovided by operations of $1,497,719.$582,589.  During 2022,2023, the Company sought to improve future cash flows from operating activities through execution of new sales agreements, improving operating cost control measures, making improvements in current manufacturing processes, pursuing new service contracts, and developing new products. The Company’s net incomeloss was $303,238$869,016 in 2022,2023, compared to net lossincome of $902,347$303,238 in 2021.2022. This is an increasea decrease in net income of $1,205,585.$1,172,254. This increasedecrease in net income is largely the result of the approximate $1.8$1.8 million gain on sale of assets.assets that occurred in 2022.

 

During the year ended December 31, 2022,2023, the Company continued to focus on its long-standing core business segments, which consist of its radiochemical products, cobalt products,Theranostics Products (formerly Radiochemical Products), Cobalt Products, and nuclear medicine standards,Nuclear Medicine Standards, and in particular, the pursuit of new business opportunities within those segments.

 

In addition to the Company’s cobalt production agreement with the DOE, the Company entered into supply agreements in 2015 with several customers for the purchase of cobalt-60. It takes several years to irradiate cobalt targets to the desired level of activity; the shipment of cobalt-60 product to these customers is delayed until cobalt that fits the customers need can be produced.  Pursuant to these cobalt-60 supply agreements, the Company will not only supply cobalt-60 to the customers but, in some instances, will also provide on-going services with respect to manufacturing and selling cobalt sources. Each contract requires quarterly progress payments to be paid by customers to the Company.

Due to changes in the nuclear industry, over the past few years, the Company’s plans for the design and construction of a large-scale uranium de-conversion and fluorine extraction facility were placed on hold. The Company expects that further activity on this project will remain on hold until the market and industry conditions change to justify resuming design and construction of the facility.  The Company will continue to incur some costs associated with the maintenance of licenses and other necessary project investments for the proposed facility, and the Company expects to continue to keep certain agreements in place to support resumption of project activities at the appropriate time. In July 2015, the Company announced that it executed an amendment to its Project Participation Agreement (PPA) with the Lea County, New Mexico Board of Commissioners. The PPA granted to the Company direct and indirect assistance for locating its proposed depleted UF6 de-conversion facility in Hobbs, New Mexico. The principal component of assistance was the conveyance of approximately 640 acres of land for construction and operation of the proposed facility.  The conveyance of the land was contingent upon the Company commencing construction on Phase 1 of the facility by December 31, 2014 and hiring a certain number of

F- 10 

employees by December 31, 2015. Under the amendment to the PPA, the Lea County, New Mexico Board of Commissioners agreed to extend those dates to December 31, 2016 and December 31, 2017, respectively. The Company did not meet the deadlines set forth in the amended PPA, but plans to continue discussions with the Lea County, New Mexico Board of Commissioners to further extend the milestone dates once contract opportunities materialize. If the Company does not succeed in extending the commitment dates or in reaching performance dates set forth in a modified agreement, then it may, at its sole option, either purchase or re-convey the property to Lea County, New Mexico. The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment.

The Company holds a Nuclear Regulatory Commission (“NRC”) construction and operating license for the depleted uranium facility as well as the property agreement with Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States. There are no other companies with a similar license application under review by the NRC. Therefore, the NRC license represents a significant competitive barrier, and the Company believes that it provides it with a very valuable asset. During 2022 In February 2024, the company has signed an OptionCompany entered into and Asset Purchase Agreement to Purchase Assets Agreementsell all the assets associated with a company that may be interested in bringing this project forward.the planned de-conversion facility. The assets under consideration include the NRC license, property agreements, and all engineering design work completed to date on the project. During 2023 the companyCompany expects to support further due diligence reviewclose the transaction in approximately 12 to 24 months, subject to satisfaction of the project by a third party that could lead to thecertain closing condition. Proceeds from this sale of these assetswould be $12.5 million in 2023 or 2024. During the year ended December 31, 2022, the Company incurred costs of approximately $145,000 to maintain licenses and other necessary project investments. During the same period in 2021, the Company incurred costs of approximately $150,000 for planning and development activities on the project.total.

 

The Company expects that cash from operations and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and voluntary warrant redemption by shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

 

F- 10

NOTE 3 – PURCHASED ASSET AND INVESTMENTS

 

Interest in RadQual, LLC

The Company had a 24.5% interest in RadQual, with which the Company has an exclusive manufacturing agreement for nuclear medicine products. On August 10, 2017, affiliates of the Company, including the Company’s Chairman of the BoardAMICI Asset Purchase Agreement and the Chief Executive Officer, acquired the remaining 75.5% interest in RadQual. As a result of this change in ownership, the Company was named as a managing member and gained the ability to exercise significant management control over the operations of RadQual. Because of this increased management ability, and pursuant to GAAP, the Company has consolidated the accounts of RadQual into its financial statements beginning as of August 10, 2017.

In July 2021, the Company purchased the remaining 75.5% interest in RadQual for an aggregate purchase price of approximately $4.4 million, which was paid in shares of our common stock, resulting in the issuance of 40,176,236 shares of our common stock as consideration. As a result of this purchase, the Company owns 100% of RadQual. The Company will continue to consolidate the accounts of RadQual as its wholly-owned subsidiary.

Acquisition of Interest in TI Services, LLCMedical Devices

 

In December 2010, June 2023, the Company togetheracquired several medical devices with RadQual, formed a 50% owned joint venture, TI Services, LLC (“TI Services”). TI Services is engaged in the distributionrelated assets and sellingintellectual property rights from AMICI, Inc. and has been working on FDA 510k transfers, and start-up of products related to the nuclear medicine industry. Because themanufacturing. The Company controls more than a 50% direct and indirect ownership interest in TI Services,anticipates the assets and liabilitieswill be part of TI Services are consolidated with thosea fifth business segment of the Company and RadQual’s non-controlling interest in TI Servicescalled “Medical Devices” that is included in the Company’s financial statements as a non-controlling interest.planned to start by mid-year 2024.

 

In July 2021, the Company purchased the remaining 75.5% interest in RadQual. As a result of the is purchase, the Company now controls 100% of TI Services. The Company will continue to consolidate the accounts of TI Services as its wholly-owned subsidiary.

F-11 

NOTE 4 – INVENTORIES

 

Inventories consisted of the following for the years ended at December 31, 2023 totaled $927,111, and inventories at December 31, 2022 and 2021:

Inventories  - Schedule totaled $744,793. Our inventory consists of Inventories, Current

  2022  2021 
Raw materials $—    $—   
Work in progress  744,793   924,775 
Finished goods  —     —   
Total Inventory $744,793  $924,775 

Included in raw material inventory raw cobalt, strontium and other raw elements. Raw material inventory is regularly reviewed for obsolescence. In 2021, the Company determined all raw material inventory was obsolete. The remaining $33,609 of raw material inventory was reduced to $0 due to this impairment.

Previously, work in process included costs to irradiate cobalt-60 material under a contract with the DOE. This material was placed in the reactor exclusively for purchase by the Company. In 2021, the company took shipment of all remaining cobalt-60 for which it had paid irradiation charges. The Company has contracted with several customers for the purchase of this cobalt-60 materialour Theranostics Products, Cobalt Products, and has collected advance payments for project management, up-front handling and irradiation charges. The advance payments from customers were recorded as unearned revenue which are recognized in the Company’s consolidated financial statements as cobalt products are completed and shipped. For the year ended December 31, 2022 and 2021, the Company recognized approximately $39,000 and $18,000, respectively, of revenue in its consolidated statements of operations for customer orders filled during the period under these cobalt contracts.Nuclear Medicine Products segments.

 

NOTE 5 – PROPERTY, PLANT AND EQUIPMENT

 

Property, plant and equipment are summarized as follows at December 31, 20222023 and 2021:

Property, Plant and Equipment - Schedule of Property, Plant and Equipment2022:

 

  2022  2021  

Estimated

Useful Lives

Furniture and fixtures Furniture and Fixtures $284,020  $199,908  3 - 5 years
Transportation equipment Transportation Equipment  114,708   114,708  5 - 10 years
Plant and improvements Plant and Improvements  501,334   1,146,312  5 years
Production equipment  3,997,193   5,807,683  5 - 10 years
   4,897,255   7,268,611   
Accumulated depreciation  (2,872,769)  (2,968,674)  
  $2,024,486  $4,299,937   
  

2023

  

2022

  Estimated Useful Lives (in years) 

Furniture and fixtures

 $287,463  $284,020   3 - 5 

Transportation equipment

  114,708   114,708   5 - 10 

Plant and improvements

  526,205   501,334   5 

Production equipment

  4,569,980   3,997,193   5 - 10 
   5,498,356   4,897,255     

Accumulated depreciation

  (3,033,279)  (2,872,769)    
  $2,465,077  $2,024,486     

 

Included in fixed assets are assets purchased during the planning phase for the construction of a de-conversion facility in Hobbs, New Mexico.Mexico; these de-conversion facility assets are included in the DUF6 Asset Sale. Although construction of the facility is currently on hold, the Company has determined that these assets continue to have future economic value based on what it considers a strong likelihood that construction of the facility will occur in the future.

 

Depreciation expense was $185,193$160,567 and $398,117$185,193 for the years ended December 31, 20222023 and 2021,2022, respectively.

 

F- 11

NOTE 6 – PATENTS AND OTHER INTANGIBLE ASSETS

 

The Company owns certain patents and patents pending related to a fluorine extraction process (FEP), for various uses of some fluoride gases as fluorinating agents, and some of the RadQual nuclear medicine calibration sources.  The FEP patents were developed in an effort to expand the potential markets for the high purity fluoride gases the Company willhad planned to produce with its fluorine extraction process. The feasibility of expanding the fluoride gas markets through the use of this patented technology is uncertain. The RadQual product patents were developed to give RadQual a unique competitive advantage by offering calibration standards exclusive to RadQual.

 

In October 2012, the NRC issued the Company a 40-year40-year construction and operating license for the de-conversion facility.  Capitalized costs associated with the licensing and planning process for this license are being amortized over the 40-year40-year life of the license.

F-12 

 

The following table summarizes the patent and intangible activity for the years ended December 31, 20222023 and 2021:

Patents and Other Intangible Assets - Schedule of Intangible Assets2022:

 

 2022  

2023

 
Beginning $5,362,628  $5,370,878 
Additions  8,250   
Disposals        
Ending  5,370,878  5,370,878 
Accumulated amortization  (1,667,525)  (1,832,420)
 $3,703,353  $3,538,458 

 

During the year ended December 31, 20222023 the Company recognized $164,370$164,895 of amortization expense, and during the year ended December 31, 2021,2022, the Company recognized $163,180$164,370 of amortization expense.

 

Patent and other intangible asset amortization is based on the remaining life of the asset and estimated amortization expense is as follows:

Patents and Other Intangible Assets - Schedule of Future Amortization Expense

Years ending December 31,

    

2025

 $164,895 

2026

  164,895 

2027

  164,895 

2028

  164,895 

2029

  164,895 

Thereafter

  2,713,983 
  $3,538,458 

 

Years ending December 31,   
2023 $164,895
2024  164,895
2025  164,895
2026  164,895
2027  164,895
Thereafter  2,878,878
  $3,703,353

F- 12

NOTE 7 – CONVERTIBLE DEBENTURES AND NOTES PAYABLE

 

Convertible debentures

Private Placement 

As discussed in Note 9 below, in February 2017, pursuant to a private placement transaction with certain investors, the Company issued 3,433 shares of Series C Preferred Stock and warrants.  In connection with the private placement, two investors holding convertible debentures exchanged aggregate principal totaling $205,000$205,000 of the convertible debentures for shares of the Series C Preferred Stock and warrants.

 

Notes payable

Chief Executive Officer 

In April 2018, the Company borrowed $120,000 from its Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021 and the 2018 Promissory Note was modified to become secured by company assets, with all other provisions remaining unchanged. Pursuant to a fifth amendment to the 2018 Promissory Note in December 2021, the maturity date was extended to December 31, 2023 with all other provisions remaining unchanged.

At December 31, 2022, accrued interest on the 2018 Promissory Note totaled $33,770.

In December 2013, the Company entered into a promissory note agreement with its then Chairman of the Board and one of its major shareholders, pursuant to which the Company borrowed $500,000$500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6%6% per annum and was originally due June 30, 2014. 2014. According to the terms of the 2013

F-13 

Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock. In connection with the 2013 Promissory Note, each of the two lenders was issued 5,000,000 Class L warrants to purchase shares of our common stock at an exercise price of $0.06 per share (Class L Warrants). The Class L Warrants were immediately exercisable. The fair value of these warrants issued totaled $384,428$384,428 and was recorded as a debt discount were amortized over the life of the 2013 Promissory Note. The Company calculated a beneficial conversion feature of $15,464$15,464 which was accreted to interest expense over the life of the 2013 Promissory Note. In June 2014, we renegotiated the terms of the 2013 Promissory Note. Pursuant to the modification, the maturity date was extended to December 31, 2017and each lender was granted an additional 7,500,000 Class L Warrants to purchasespurchase shares of the Company’s common stock at an exercise price of $0.06 per share. The Class L Warrants were immediately exercisable. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020,, with all remaining terms unchanged. On December 23, 2018, all 25,000,000 Class L Warrants expired. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021,, with all remaining terms unchanged. In January 2022, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2023,, with all remaining terms unchanged. In February 2024, the 2013 Promissory Note was further modified to extend the maturity date to March 31, 2026, with all remaining terms unchanged.

 

At December 31, 2022, the principal balance of the 2013 Promissory Note was $500,000 and2023, accrued interest payable on the 2013 Promissory Note was $271,734. Interest expense recorded for the year ended December 31, 2022, was $30,000.$301,734.

 

In April 2019, one2018, the Company borrowed $120,000 from its then Chief Executive Officer and Chairman of the prepaid revenue customers requestedBoard pursuant to a refundpromissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the amounts paid.2018 Promissory Note. The Company entered into a note agreement2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to repay $2,182,142have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the next 12 months. The modificationprevious 20 trading days. In June 2018, the 2018 Promissory Note was necessarymodified to addressextend the delaysmaturity date to cobalt delivery inMarch 31, 2019 caused by changeswith all other provisions remaining unchanged. In February 2019, the 2018 Promissory Note was modified to extend the ATR operating schedule and alsomaturity date to accommodate this customer’s requestJuly 31, 2019 with all other provisions remaining unchanged. In July 2019, the 2018 Promissory Note was modified to reduce their cobalt purchase obligations in future years. The modifications require thatextend the Company refund approximately $1,050,000 of payments received for prior year undelivered material, plus interest at 12% per year, payable over a one-year period on a portion of that amount. The Company has also agreed maturity date to January 31, 2020 with this customer to refund approximately $1,100,000 paid for material that was to have been delivered in later years. There will be no interest charge on this refund.all other provisions remaining unchanged. In December 2019, this agreementthe 2018 Promissory Note was modified further allowingto extend the Companymaturity date to delay the original payments by 3 months and refund an additional $462,858 with no interest charge. At December 31, 2021 balance on this refund is $80,000. This refundand the 2018 Promissory Note was paid in full in modified to become secured by company assets, with all other provisions remaining unchanged. In December 2021, the 2018 Promissory Note was modified to extend the maturity date to December 31, 2023 with all other provisions remaining unchanged. In December 2023, the 2018 Promissory Note was modified to extend the maturity date to January 31, 2025. In February 2022.2024, the 2018 Promissory Note was modified to extend the maturity date to March 31, 2026.

 

In August 2021, one of the prepaid revenue customers requested a refund of the amounts paid. The Company entered into a note agreement to repay $146,072 by June 2021. Any balance of the refund amount left outstanding after At December 31, 2021 accrues2023, accrued interest at a rate of 5% per annum until paid in full. At December, 31, 2021 balance on this refund is $146,072. This refund was paid in full in February 2022.the 2018 Promissory Note totaled $40,970.

Subsequent Event 

On December 20, 2019, the Company entered into a promissory note agreement with four of the Company’s major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes the Company to borrow up to $1,000,000.$1,000,000. As of December 31, 2019, the Company had borrowed $675,000$675,000 under the 2019 promissory note. In February 2020, the Company borrowed an additional $325,000.$325,000. The 2019 Promissory Note bears an interest rate of 4%4% annually and iswas originally due December 31, 2022. 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 trading days preceding the payment. In connection with the 2019 Promissory Note, the lenders were issued warrants totaling 30,000,000 warrants to purchase shares of the Company’s common stock at $0.045$0.045 per share (Class O Warrants). The fair value of these Class O Warrants issued totaled $446,079 and was recorded as a debt discount and was amortized over the life of the 2019 Promissory Note. At December 31, 2022, the remaining balance of this debt discount was $0. The Company calculated a beneficial conversion feature of $315,643 which was accreted to interest expense over the life of the 2019 Promissory Note. At December 31, 2022, the remaining balance of this beneficial conversion feature was $0. In January 2023, the 2019 Promissory Note was modified to extend the maturity date to December 31, 2024,, with all remaining terms unchanged. In February 2024, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2026.

At December 31, 20222023, accrued interest on the 2019 Promissory Note totaled $119,131.$159,131.

 

In April 2021, the Company borrowed $250,000 from its Chief Executive Officer and Chairman

F- 13

Notes payable as of December 31, 20222023 and 20212022 consist of the following:

Convertible Debentures and Notes Payable - Schedule of Long-term Debt Instruments

  2022  2021 
Notes Payable      
Note payable to related parties bearing interest at 6% all principal and interest due on December 31, 2023, secured $120,000  $120,000 
Note payable to related parties bearing interest at 6% all principal and interest due on December 31, 2022, secured       250,000 
Note payable to related parties net of unamortized debt discount of $0 and $256,265 at December 31, 2022 and 2021, respectively, bearing interest at 4% all principal and interest due on December 31, 2024, secured  1,000,000   743,735 
Note payable to related parties bearing interest at 6% all principal and interest due on December 31, 2023, secured  500,000   500,000 
Note payable to customer pursuant to a refund agreement. Interest at 12%       80,000 
Note payable to customer pursuant to a refund agreement. Interest at 5%       146,072 
Note payable to a financial institution bearing interest at 6.66% monthly installments of $805, secured       3,167 
Note payable to a financial institution bearing interest at 5.99% monthly installments of $1,046, secured  44,521   54,087 
Note payable for purchase contract bearing interest at 5% monthly installments of $4,442, secured  13,233   64,460 
Total notes payable  1,677,754   1,961,521 
Less: current maturities  (643,348)  (1,283,752)
Notes payable, net of current installments and debt discount $1,034,406  $677,769 
  

2023

  

2022

 
         

Note payable to related parties bearing interest at 6% all principal and interest due on March 31, 2026, secured

 $120,000  $120,000 

Note payable to related parties bearing interest at 4% all principal and interest due on March 31, 2026, secured

  1,000,000   1,000,000 

Note payable to related parties bearing interest at 6% all principal and interest due on March 31, 2026, secured

  500,000   500,000 

Note payable to a financial institution bearing interest at 5.99% monthly installments of $1,046, secured

  34,365   44,521 

Note payable for purchase contract bearing interest at 5% monthly installments of $4,442, secured

     13,233 

Note payable for purchase contract bearing no interest until the 25th month after the anniversary of the closing interest at 8% thereafter monthly installments of $10,000

  392,100    

Total notes payable

  2,046,465   1,677,754 

Less: current maturities

  (155,733)  (643,348)

Notes payable, net of current installments and debt discount

 $1,890,732  $1,034,406 

 

Maturities of convertible debt and notes payable, excluding debt discount and debt issuance costs, at December 31, 2022,2023, are as follows:

Convertible Debentures and Notes Payable - Schedule of Maturities of Long-term Debt

Years ending December 31,

    

2024

 $155,733 

2025

  124,838 

2026

  1,745,595 

2027

  20,299 

Thereafter

   
  $2,046,465 

 

Years ending December 31,    
2023  $643,348 
2024   1,010,774 
2025   11,439 
2026   12,193 
Thereafter   —   
   $1,677,754 

F- 14

NOTE 8 – LEASE OBLIGATIONS

 

The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company’s leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease may be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease.

 

F-15 

     
 Year Ended  

Year Ended

 
 December 31  

December 31,

 
 2022 2021  

2023

  

2022

 
Operating lease costs $285,159  $258,762  $287,108  $285,159 
Short-term operating lease costs  12,066   6,003  7,200  12,066 
Financing lease expense:         
Amortization of right-of-use assets  4,172   7,786  6,023  4,172 
Interest on lease liabilities  649   1,855   395   649 
Total financing lease expense  4,821   9,641   6,418   4,821 
Total lease expense $302,046  $274,406  $300,726  $302,046 
         
Right-of-use assets obtained in exchange for new operating lease liabilities $  $1,603  $  $ 
Right-of-use assets obtained in exchange for new financing lease liabilities $—    $—    $  $ 
Weighted-average remaining lease term (years) - operating leases  12.1   13.1  11.1  12.1 
Weighted-average remaining lease term (years) - financing leases  1.1   2.1  1.2  1.1 
Weighted-average discount rate - operating leases  6.75%  6.75% 6.75% 6.75%
Weighted-average discount rate - financing leases  7.93%  8.63% 6.75% 7.93%

 

Maturities of lease liabilities as of December 31, 2022,2023, were as follows:

Lease Obligations - Schedule of  Maturities of Operating and Finance Lease Liabilities

  

Operating leases

  

Finance leases

 

For the years ended December 31,

        

2024

 $287,108  $2,929 

2025

  287,108    

2026

  287,108    

2027

  287,108    

2028

  287,108    

Thereafter

  1,738,084    

Total minimum lease obligations

  3,173,624   2,929 

Less-amount representing interest

  (941,380)  (97)

Present value of minimum lease obligations

  2,232,244   2,832 

Current maturities

  (140,733)  (2,832)

Lease obligations, net of current maturities

 $2,091,511  $ 

 

 Operating leases Finance leases
For the years ended December 31,     
2023$287,108  $5,881 
2024 287,108   2,929 
2025 287,108   — 
2026 287,108   — 
2027 287,108   — 
Thereafter 2,025,193   — 
Total minimum lease obligations 3,460,733   8,810 
Less-amount representing interest (1,096,917)  (465)
Present value of minimum lease obligations 2,363,816   8,345 
Current maturities (131,572)  (5,513)
Lease obligations, net of current maturities$2,232,244  $2,832 

F- 15

NOTE 9 – SHAREHOLDERS’ EQUITY, REDEEMABLE CONVERTIBLE PREFERRED STOCK, OPTIONS AND WARRANTS

 

Warrants

 

In December 2019, the Company entered into the 2019 Promissory Note, as discussed above. In connection with the 2019 Promissory Note, the company issued 20,250,000 Class O Warrants to purchase shares of the Company’s common stock at a purchase price of $0.045 per share. All 20,250,000 Class O Warrants were exercised in January 2021.

In February 2020, the Company borrowed the remaining amount available for borrowings under the 2019 Promissory Note as discussed above. As a result and according to the terms of the 2019 Promissory Note, the Company issued 9,750,000 additional Class O Warrants to purchase shares of the Company’s common stock at a purchase price of $0.045 per share. All 9,750,000 Class O Warrants were exercised in January 2021.

On February 14, 2022, 515,000 Class M Warrants were exercised for an exercise price of $0.12$0.12 per share. The Company received $61,800$61,800 of proceeds as a result of the exercise. On February 17, 2022 the 3,625,000 remaining unexercised Class M Warrants expired. On May 12, 2022, the 2,925,000 remaining unexercised Class N Warrants expired.

F-16 

 

The following table summarizes warrant activity for the years ended December 31, 20222023 and 2021:

Shareholders’ Equity, Redeemable Convertible Preferred Stock, Options and Warrants - Schedule of Warrant Activity2022:

 

Warrants Outstanding Shares 

Weighted

Average

Exercise

  

Outstanding Shares

  

Weighted Average Exercise

 
Outstanding at December 31, 2020   50,090,000  $0.07 
Granted —    
Exercised (43,025,000) 0.07 
Forfeited  —    —  
Outstanding at December 31, 2021 7,065,000 0.11  7,065,000  $0.11 
Granted —         
Exercised (515,000) 0.12  (515,000)  0.12 
Forfeited  (6,550,000)  0.11   (6,550,000)  0.11 
Outstanding at December 31, 2022  —    $      

Granted

     

Exercised

     

Forfeited

      

Outstanding at December 31, 2023

    $ 

 

At December 31, 2023 and December 31, 2022 there were no outstanding warrants.

 

Warrants outstanding at December 31, 2021, included 4,140,000 Class M Warrants which were immediately exercisable at an exercise price of $0.12 per share and expired on February 17, 2022; 2,925,000 Class N Warrants which are immediately exercisable at an exercise price of $0.10 per share and expire on May 12, 2022.

 

Mandatorily Redeemable Convertible Preferred Stock

 

The Company is authorized to issue up to 5,000,000 shares of preferred stock, par value $0.01$0.01 per share. The Board is authorized to set the distinguishing characteristics of each series prior to issuance, including the granting of limited or full voting rights, rights to the payment of dividends and amounts payable in event of liquidation, dissolution or winding up of the Company.

 

At December 31, 2021, there were 675 shares of the Series B Convertible Redeemable Preferred Stock (the “Series B Preferred Stock”) outstanding with a mandatory redemption date of May 2022 at $1,000$1,000 per share, or $675,000$675,000 in aggregate redemption value. The Series B Preferred Stock were convertible into common stock at a conversion price of $2.00$2.00 per share. These preferred shares carried no dividend preferences. Due to the mandatory redemption provision, the Series B Preferred Stock were classified as a liability in the accompanying consolidated balance sheets. In 2021,175 shares of Series C Preferred Stock were converted into shares of common stock. On May 31, 2022, the Company paid with shares of the Company’s common stock all 675 outstanding Series B Preferred Stock outstanding with a mandatory redemption date of May 2022 at $1,000$1,000 per share or $675,000.$675,000. The May 31, 2022 average price of the Company’s common stock was $0.08$0.08 per share. The Company issued 8,437,500 shares of common stock to satisfy the $675,000$675,000 redemption amount.

 

At December 31, 2021 and December 31, 2022 and December 31, 2023, there were 4,063 total shares of the Series C Preferred Stock outstanding. The Series C Preferred Stock are convertible at the option of the investors at any time into shares of the Company's common stock at an initial conversion price equal to $0.10$0.10 per share, subject to adjustment. At any time after February 17, 2019, if the volume-weighted average closing price of the Company’s common stock over a period of 90 consecutive trading days is greater than $0.25 per share, the Company may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share ($1,000) plus any accrued and unpaid dividends, payable in shares of common stock. All outstanding shares of Series C Preferred Stock were to be redeemed by the Company on February 17, 2022 at the original purchase price per share, payable in cash or shares of common stock, at the option of the holder. In February 2022, based on approval of a majority of the Preferred C Holders, the Company extended the redemption date of the Series C Preferred Stock to February 17, 2023. In December 2022, based on approval of a majority of the Preferred C Holders, the Company extended the redemption date of the Series C Preferred Stock to February 17, 2025. Holders of Series C Preferred Stock do not have any voting rights, except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock.

 

The Company pays dividends on the Series C Preferred Stock in February each year. Dividends payable totaled $243,780$243,780 in February 2022 2023 and $254,280 in February 2021. 2022. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. The Company issued 2,271,9802,266,500 shares of common stock in lieu of a dividend payment of $204,480$90,660 in 20222023 and 1,398,2002,271,980 shares of common stock in lieu of a dividend payment of $205,980$204,480 in 2021. $39,3002022. $153,120 of dividend payable was settled with cash in 20222023 and $46,800$39,300 was settled with cash in 2021.2022.

 

F- 16

F-17 

The outstanding 4,063 shares of Series C Preferred Stock originated as follows:

 

On February 17, 2017, the Company entered into subscription agreements with certain investors, including two of the Company’s directors, for the sale of (i) an aggregate of 3,433 shares of Series C Preferred Stock, and (ii) Class M warrants to purchase an aggregate of 17,165,000 shares of the Company’s common stock (the Class M Warrants), for gross proceeds of $3,433,000.$3,433,000. The Series C Preferred Stock accrues dividends at a rate of 6%6% per annum, payable annually on February 17th of each year, commencing on February 17, 2018.

 

The Class M Warrants were immediately exercisable at an exercise price of $0.12 $0.12 per share, subject to adjustment as set forth in the warrant, and expired in February 2022.

 

The Company allocated the proceeds to the Series C Preferred Stock and Class M Warrants based on their relative fair value, which resulted in $2,895,379$2,895,379 being allocated to the Series C Preferred Stock and $537,621$537,621 being allocated to the Class M Warrants. The allocated Class M Warrant value was recorded as a discount to the Series C Preferred Stock and will be amortized to interest expense over the five-yearfive-year life of the warrants. At December 31, 2021,2022, the balance of the discount to the Series C Preferred Stock was $13,440$13,440 and the net carrying value of these 3,433 shares of Series C Preferred Stock was $3,419,560.$3,419,560. At December 31, 2022,2023, the balance of the discount to the Series C Preferred Stock was $0$0 and the net carrying value of these 3,433 shares of Series C Preferred Stock was $3,433,000.$3,433,000.

 

On March 24, 2017, the Company entered into an Amendment to the 8% Convertible Notes (the Amendment), pursuant to which the 8% Convertible Notes (the Notes) issued by the Company in July 2012 were amended to give noteholders certain additional rights. Pursuant to the Amendment, the Notes were modified to provide each holder the right, at the holder’s option and exercisable prior to May 12, 2017, to convert all or any portion of the principal amount of the Notes, plus accrued but unpaid interest, into shares of Series C Preferred Stock at a conversion price of $1,000$1,000 per share. Holders that elected to convert their Notes into Series C Preferred Stock received a Class N Warrant to purchase up to 3,750 shares of the Company’s common stock for each share of Series C Preferred Stock received upon conversion of the Notes, with each Warrant having a five-yearfive-year term, a cashless exercise feature, and an exercise price of $0.10 per share of common stock. On May 12, 2017, the Company completed the retirement of $1,835,000$1,835,000 of the Notes in early cash redemptions, and $780,000$780,000 of the Notes were converted into an aggregate of 780 shares of Series C Preferred Stock and Class N Warrants to purchase an aggregate of 2,925,000 shares of the Company’s common stock. In 2021,150 shares of Series C Preferred Stock were converted into shares of common stock.

 

The Class N Warrants were immediately exercisable at an exercise price of $0.10$0.10 per share, subject to adjustment as set forth in the warrant, and expired in May 2022.

 

The Company allocated the proceeds to the Series C Preferred Stock and Class N Warrants based on their relative fair value, which resulted in $675,947$675,947 being allocated to the Series C Preferred Stock and $104,053$104,053 being allocated to the Class N Warrants. The allocated Class N Warrant value was recorded as a discount to the Series C Preferred Stock and will be amortized to interest expense over the five-yearfive-year life of the warrants. At December 31, 2021,2022, the balance of the discount to the Series C Preferred Stock was $4,737$4,737 and the net carrying value of 630 outstanding shares of Series C Preferred Stock was $625,263.$625,263. At December 31, 2022,2023, the balance of the discount to the Series C Preferred Stock was $0$0 and the net carrying value of 630 shares of Series C Preferred Stock was $630,000.$630,000.

 

Employee Stock Purchase Plan

 

In September 2004, the Company’s Board approved an employee stock purchase plan for an aggregate of up to 2,000,000 shares of the Company’s common stock. The plan allows employees to deduct up to 15% of their salary or wages each pay period to be used for the purchase of common stock at a discounted rate. The common shares will be purchased at the end of each three-monththree-month offering period or other period as determined by the Board. The plan is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code. An amendment and restatement of the plan was approved in July 2020 by the Company’s shareholders, which increased the number of shares available for purchase by 3,000,000 shares. At December 31, 20222023 there were 2,541,4102,224,544 shares available under the employee stock purchase plan.

 

During 20222023 and 2021,2022, the Company issued 245,081316,866 and 313,420245,081 shares of common stock to employees for proceeds of $14,771$8,398 and $18,888,$14,771, respectively, in accordance with the employee stock purchase plan.

 

F-18 

F- 17

2015 Incentive Plan

 

In April 2015, the Company’s Board of Directors approved the International Isotopes Inc. 2015 Incentive Plan (as amended, the “2015“2015 Plan”,) which was subsequently approved by the Company’s shareholders in July 2015. The 2015 Plan was amended and restated in July 2018 to increase the number of shares authorized for issuance under the 2015 plan by an additional 20,000,000 shares. The 2015 Plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock or cash-based awards.  The 2015 Plan amends and restates the Company’s Amended and Restated 2006 Equity Incentive Plan (the “2006“2006 Plan”).

 

The 2015 Plan authorizes the issuance of up to 80,000,000 shares of common stock, plus 11,089,967 shares authorized, but not issued under the 2006 Plan. Unless earlier terminated, the 2015 Plan will terminate on July 13, 2025. At December 31, 20222023 there were 29,401,13420,292,546 shares available for issuance under the 2015 Plan.

 

Non-Vested Stock Grants

 

Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded 307,692560,000 fully vested shares of common stock to its then Chief Executive Officer in February 2022 2023 under the 2015 Plan. The number of shares awarded was based on a $28,000$28,000 stock award using a price of $0.091$0.05 per share. The employment agreement provides that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grant was $27,692,$22,400, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 28, 2021, 2023, which was $0.09$0.04 per share. The Company withheld 120,461216,440 shares of common stock to satisfy the employee’s payroll tax obligations in connection with this issuance. The net shares issued on February 28, 2022 2023 totaled 187,231.343,560.

 

Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded 195,804307,692 fully vested shares of common stock to its Chief Executive Officer in February 2021 2022 under the 2015 Plan. The number of shares awarded was based on a $28,000$28,000 stock award using a price of $0.143$0.091 per share. The employment agreement provides that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grant was $23,496,$27,692, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 28, 2021, which was $0.12$0.09 per share. The Company withheld 77,489120,461 shares of common stock to satisfy the employee’s payroll tax obligations in connection with this issuance. The net shares issued on February 28, 2021 2022 totaled 118,315.187,231.

 

Stock Options

 

A summary of the stock options issued under the Company’s equity plans is as follows:

Shareholders’ Equity, Redeemable Convertible Preferred Stock, Options and Warrants - Schedule of Stock Option Activity

     Weighted   
   Weighted Average   
   Average Remaining Average 
 Outstanding Exercise Contractual Intrinsic 
Warrants Shares Price Life Value 
Outstanding at December 31, 2020 20,400,000 $0.06   $107,250 
Granted 3,250,000 0.11     
Exercised (2,552,500) 0.04   362,410 
Forfeited  (320,000) 0.07     

Stock Options

 Outstanding Shares  

Weighted Average Exercise Price

  

Weighted Average Remaining Contractual Life

  

Average Intrinsic Value

 
Outstanding at December 31, 2021 20,777,500 0.06   627,615  20,777,500   0.06      627,615 
Granted 8,150,000 0.09      8,150,000  0.09      
Exercised (1,200,000) 0.04   57,000  (1,200,000) 0.04     57,000 
Forfeited  (1,734,000) 0.08       (1,734,000) 0.08      
Outstanding at December 31, 2022  24,993,500 0.07 6.0 —    24,993,500  0.07      
Exercisable at December 31, 2022  16,716,000 $0.06 4.6 $   

Granted

 3,100,000  0.04      

Exercised

          

Forfeited

  (3,306,000) 0.08      

Outstanding at December 31, 2023

  24,787,500  0.05  5.4  17,000 

Exercisable at December 31, 2023

  19,372,500  $0.05  4.6  $16,000 

 

The total intrinsic value of stock options outstanding at December 31, 20222023 was $0. 16,000. The intrinsic value for stock options outstanding is calculated as the amount by which the quoted price of $0.03$0.04 of the Company’s common stock as of the end of 20222023 exceeds the exercise price of the options.

 

F-19 

F- 18

The Company recognized $280,393$199,554 and $70,366$280,393 of compensation expense related to these options for the years ended December 31, 20222023 and 2021,2022, respectively. At December 31, 2022,2023, the remaining compensation expense was $170,591$99,768 and will be recognized over 1.881.71 years.

 

During the year ended December 31, 2023, no qualified stock options were exercised.

In March 2022, 1,000,000 qualified stock options were exercised under a cashless exercise. The company withheld 388,889 shares to satisfy the exercise price and issued 611,111 shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2022.2023.

 

In August 2022, 200,000 qualified stock options were exercised under a cashless exercise. The company withheld 162,163 shares to satisfy the exercise price and issued 37,837 shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2022.2023.

 

In January 2021, 2,000,000 qualified stock options were exercised under a cashless exercise. The company withheld 250,000 shares to satisfy the exercise price and issued 1,750,000 shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2021.

In January 2021, 62,500 qualified stock options were exercised under a cashless exercise. The company withheld 13,393 shares to satisfy the exercise price and issued 49,107 shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2021.

In September 2021, 200,000 qualified stock options were exercised under a cashless exercise. The company withheld 90,909 shares to satisfy the exercise price and issued 109,091 shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2021.

In December 2021, 290,000 qualified stock options were exercised under a cashless exercise. The company withheld 173,400 shares to satisfy the exercise price and issued 116,600 shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2021.

Employee

Members of the Board

During the year ended December 31, 2022, 2023the Company granted an employee 1,000,000aggregate of 3,100,000 qualified stock options with an exercise priceto 32 of $0.10 per share and 25,000 qualified stock options with an exercise price of $0.08 per share to one of its employees and a total of 125,000 qualified stock options with an exercise price of $0.03 per share to two other employees. These options vest over a five-year period with the first vesting at the one-year anniversarydate of the grant and expiration at ten-yearten-year anniversary for all grants. On February 21, 2022, the Compensation Committee granted 3,000,000 qualified stock options to the Company’s executive officers and 4,000,000 non-qualified stock options to members of the Board. The exercise price for these granted options was $0.09$0.04 and $0.06 per share. 2,000,000 of the options granted to an executive officer vest one half immediately and one half at the one-year anniversary of the grant. The remaining executive officer and board member options vest one fourth immediately and one fourth each subsequent year. All these granted options expire at the ten-year anniversary of the grant. The options issued during the year ended December 31, 20222023 have a fair value of $442,295$82,176, as estimated on the date of issue using the Black-Scholes options pricing model with the following weighted-average assumptions: risk free interest rate of 1.37%3.94% to 4.14%4.26%, expected dividend yield rate of 0%0%, expected volatility of 65.19%68.65% to 70.09%79.21% and an expected life between 5 and 7.57 years.

Executive Officers

 

During the year ended December 31, 2021,2022, the Company granted an employee 1,000,000 qualified stock options with an exercise price of $0.10 per share and 25,000 qualified stock options with an exercise price of $0.08 per share to one of its employees and a total of 125,000 qualified stock options with an exercise price of $0.03 per share to two other employees. These options vest over a 3,250,000five-year period with the first vesting at the one-year anniversary of the grant and expiration at ten-year anniversary for all grants. On February 21, 2022, the Compensation Committee granted 3,000,000 qualified stock options to severalthe Company’s executive officers and 4,000,000 non-qualified stock options to members of its employees. All options vest over a five-year period with the first vesting at one-year anniversary for all grants and expiration at ten-year anniversary for all grants.Board. The weighted average exercise price for these options was $0.11$0.09 per share. 2,000,000 of the options granted to an executive officer vest one half immediately and one half at the one-year anniversary of the grant. The remaining executive officer and board member options vest onefourth immediately and onefourth each subsequent year. All these granted options expire at the ten-year anniversary of the grant. The options issued during the year ended December 31, 2022 have a fair value of $209,748$442,295 as estimated on the date of issue using the Black-Scholes options pricing model with the following weighted-average assumptions: risk free interest rate of 0.46%1.37% to 1.44%4.14%, expected dividend yield rate of 0%0%, expected volatility of 52.52%65.19% to 69.01%70.09% and an expected life between 5.55 and 7.5 years.

Minimum

Maximum

 

All options exercised were issued under a qualified plan and accordingly, there is no income tax effect in the accompanying financial statements.

 

F- 19

F-20 Restricted Stock Units

 

A summary of the non-vested restricted stock units issued under the Company’s equity plans is as follows:

 

Non-Vested Restricted Stock Units

 

Number of restricted stock units

 

Weighted average grant-date fair value

Outstanding at December 31, 2020

 

 

$ —

Granted

 

 

Exercised

 

 

Forfeited

 

 

Outstanding at December 31, 2021

 

 

Granted

 

 

Vested

 

 

Forfeited / Cancelled

 

 

Outstanding at December 31, 2022

 

 

Granted

 

7,250,000

 

0.04

Vested

 

(250,000

)

0.04

Forfeited / Cancelled

 

 

Outstanding at December 31, 2023

 

7,000,000

 

$ 0.04

The Company recognized $121,202 and $0 of compensation expense related to these restricted stock units ("RSU") for the years ended December 31, 2023 and 2022, respectively. At December 31, 2023, the remaining compensation expense was $168,798 and will be recognized over 1.72 years.

On March 3, 2023, the Compensation Committee of our Board of Directors approved the cancellation of 1,000,000 outstanding stock options held by a member of the Board in exchange for the grant of 750,000 RSUs. The RSUs vest over a three-year period beginning on the grant date.

On May 8, 2023, pursuant to an executive employment agreement entered into with its newly appointed President, the Company granted 6,500,000 RSUs to its President. 1,500,000 RSUs vest on April 17, 2024, 2,000,000 RSUs vest on April 17, 2025, and 3,000,000 RSUs vest on April 17, 2026. Each RSU represents the contingent right to receive one share of the Company’s common stock.

On September 5, 2023, pursuant to an employment agreement with its President, the Company awarded 2,500,000 fully vested RSUs under the 2015 Plan to the Company's President upon his promotion to Chief Executive Officer. Compensation expense recorded pursuant to this RSU award was $150,000, which was determined by multiplying the number of shares awarded by the closing price of the common stock on September 5, 2023, which was $0.06 per share. The Company withheld 778,972 shares of common stock to satisfy payroll tax obligations in connection with this issuance. The net shares issued on September 5, 2023 totaled 1,721,028.

F- 20


NOTE 10 – INCOME TAXES - TO BE UPDATED

 

The Company paid no federal or state income taxes during 20222023 and 2021.2022. Income tax benefit on losses differed from the amounts computed by applying the recently enacted U.S. federal income tax rate of 21% to pretax losses as a result of the following:

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation

 2022  2021  

2023

  

2022

 
Income tax expense (benefit) $72,207 $(189,493 $(182,493) $72,207 
Book and tax differences  (72,207)  (36,981 40,577  (72,207)
State taxes net of federal benefit            
Change in valuation allowance     226,474  141,916    
Total Income Tax Expense $—    $—   
 $  $ 

 

The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets (liabilities) as of December 31, 20222023 and 20212022 are presented below:

Income Taxes - Schedule of Deferred Tax Assets and Liabilities

 2022  2021  

2023

  

2022

 
Deferred income tax asset $—    $—    $  $ 
Net operating loss carryforward  7,736,618   7,915,642  7,918,996  7,736,618 
Valuation allowance  (7,363,815)  (7,497,326)  (7,476,180)  (7,363,815)
Total deferred income tax asset  327,803   418,316  442,816  372,803 
Deferred income tax liability - depreciation  (372,803)  (418,316)  (442,816)  (372,803)
Deferred tax asset (liability) $—    $—    $  $ 

 

At December 31, 2022,2023, the Company had net operating losses of approximately $36,841,000$37,000,000 that will begin to expire in 2024. The valuation allowances for 20222023 and 20212022 have been applied to offset the deferred tax assets in recognition of the uncertainty that such benefits will be realized.

 

In accordance with GAAP, the Company has analyzed its filing positions in all jurisdictions where it is required to file income tax returns for the open tax years in such jurisdictions. The Company currently believes that all significant filing positions are highly certain and that all of its significant income tax filing positions and deductions would be sustained upon audit. Therefore, the Company has no significant reserves for uncertain tax positions, and no adjustment to such reserves was required by GAAP. No interest or penalties have been levied against the Company and none are anticipated, therefore no interest or penalty has been included in the provision for income taxes in the consolidated statements of operations.

 

The Internal Revenue Code contains provisions which reduce or limit the availability and utilization of net operating loss carry forwards in the event of a more than 50% change in ownership. If such an ownership change occurs with the Company, the use of these net operating losses could be limited.

 

F- 21

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Dependence on Third Parties

Sales

Customer Concentration 

Sales during 20222023 to the Company’s top three customers was approximately 23%22% of its total gross revenue. The Company is making efforts to reduce its dependency on a small number of customers by expanding both domestic and foreign.

 

The production of HSA Cobalt is dependent upon the DOE, and its prime operating contractor, which controls the reactor and laboratory operations at the ATR located outside of Idaho Falls, Idaho.  On October 2, 2014, the Company signed a ten-yearten-year contract with the DOE for the irradiation of cobalt targets for the production of cobalt-60.cobalt-60. The Company will be able to purchase cobalt targets for a fixed price per target and with an annual 5% escalation in price.  The contract term is October 1, 2014, through September 30, 2024.  However, the DOE may end the contract if it determines termination is necessary for the national defense, security or environmental safety of the U.S.  If this were to occur, all payments made by the Company would be refunded.

 

The key isotope materials used to manufacture our radiopharmaceutical product and nuclear medicine reference standards are supplied to the Company through agreements with several suppliers. The loss of any of these suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales.

 

F-21 

Contingencies

 

Because all the Company’s business segments involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted within the Company’s facility.  Although this license does not currently restrict the volume of business operation performed or projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would permit processing of other reactor-produced radioisotopes by the Company.  The financial assurance required by the NRC to support this license has been provided for with a surety bond and a restricted money market account, in the amount of $840,049,$880,752, held with North American Specialty Insurance Company and Merrill Lynch, respectively.

 

In August 2011, we received land from Lea County, New Mexico, pursuant to a PPA, whereby the land was deeded to us for no monetary consideration. In return, we committed to construct a uranium de-conversion and FEP facility on the land.  In order to retain title to the property, we were to begin construction of the de-conversion facility no later than December 31, 2014, and complete Phase I of the project and have hired at least 75 persons to operate the facility no later than December 31, 2015, although commercial operations need not have begun by that date. In 2015 the Company negotiated a modification to the PPA agreement that extended the start of construction date to December 31, 2015, and the hiring milestone to December 31, 2016.  Those dates were not met and the Company is currently in the process of renegotiating a second modification to the agreement to further extend those dates. If we do not succeed in reaching an amendment to extend the performance dates in the agreement then we may, at our sole option, either purchase or re-convey the property to Lea County, New Mexico.  The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment.  We have not recorded the value of this property as an asset and will not do so until such time that sufficient progress on the project has been made to meet our obligations under the agreements for permanent transfer of the title.

 

Defined Contribution Pension Plan

 

The Company has a 401(k)401(k) defined-contribution pension plan (the “401(k)“401(k) Plan”).  Employees are eligible to participate in the Plan after completing six months of full-time service. Participants, under provision of Internal Revenue Code § 401(k)401(k), may elect to contribute up to $20,500$23,000 of their compensation to the 401(k)401(k) Plan which includes both before-tax and Roth after-tax contribution options. Although the Company reserves the right to make discretionary matching contributions to participant accounts, there were There was no employer matching contributions made for either 2021 or 2020.2022. Beginning in 2023, the Company began matching contributions according to safe harbor 401(k) rules. All amounts withheld for employee contributions for 20212023 were paid into the 401(k)401(k) Plan. The employer reserves the right to terminate the 401(k)401(k) Plan at any time.

 

F- 22

NOTE 12 – ASSET RETIREMENT OBLIGATION

 

As part of the Company’s NRC operating license and as part of the Company’s facility lease agreements, the Company is responsible for decommissioning any facilities upon termination or relocation of operations. The Company has developed a decommissioning funding plan using guidelines provided by the NRC and has estimated the cost of decommissioning the facility in Idaho Falls. The decommissioning cost estimate is reviewed at least annually to validate the assumptions and is revised as necessary when changes in the facility processes or radiological characteristics would affect the cost of decommissioning.

 

In accordance with GAAP, the Company has recognized future estimated decommissioning costs as an asset retirement obligation and a related capitalized lease disposal cost. The Company has recognized period-to-period changes in the liability (accretion) in the statement of operations as amortization expense. Changes resulting from revisions to the original estimate are recorded as an increase or decrease to the capitalized lease disposal cost. Capitalized lease disposal cost is amortized on a straight-line basis over the remaining life of the facility operating lease agreement.

 

The following summarizes the activity of the asset retirement obligation for the years ended December 31, 20222023 and 2021:

Asset Retirement Obligation - Schedule of Asset Retirement Obligation Activity2022:

 

Obligation for Lease

Disposal Cost

 

Obligation for Lease Disposal Cost

 
Balance at December 31, 2020$588,105
Increase in lease disposal costs 260,715
Accretion expense/amortization expense 43,267
Balance at December 31, 2021 892,087  892,087 
Increase in lease disposal costs    
Accretion expense/amortization expense 50,291  50,291 
Balance at December 31, 2022$942,378 942,378 

Increase in lease disposal costs

 478,959 

Accretion expense/amortization expense

  53,126 

Balance at December 31, 2023

 $1,474,463 

 

 

F-22 

NOTE 13 – FAIR VALUE MEASUREMENTS

 

At December 31, 20222023 and 2021,2022, the Company had no assets carried at fair value.

 

F- 23

NOTE 14 – REVENUE RECOGNITION

 

Revenue from Product Sales

 

The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data:

Revenue Recognition - Summary of Sales from Contracts with Customers Disaggregated by Business Segment and Geography

Outside U.S. Twelve Months Ended December 31, 2022  Twelve Months Ended December 31, 2021 
 U.S. 

Outside

U.S.

 

Total

Revenues

 

% of Total

Revenues

  U.S. 

Outside

U.S.

 

Total

Revenues

 

% of Total

Revenues

  

Twelve Months Ended December 31, 2023

  

Twelve Months Ended December 31, 2022

 
Radiochemical Products $5,338,010 $707,757 $6,045,767 54% $3,774,471 $500,573 $4,275,044 44%
 

U.S.

  Outside U.S.  Total Revenues  

% of Total Revenues

  

U.S.

  Outside U.S.  Total Revenues  

% of Total Revenues

 

Theranostics Products

 $5,685,244  $1,157,654  $6,842,898  56% $5,338,010  $707,757  $6,045,767  54%
Cobalt Products  1,137,066 20,470 1,157,536 10%  1,299,503 55,014 1,354,517 14% 932,915  104,158  1,037,073  8% 1,137,066  20,470  1,157,536  10%
Nuclear Medicine Products  3,173,755 804,930 3,978,685 36%  3,095,123 907,483 4,002,606 42% 3,405,508  981,906  4,387,414  36% 3,173,755  804,930  3,978,685  36%
Fluorine Products  —    —    —   0%  29,775  —    29,775 0%           0%           0%
 $9,648,831 $1,533,157 $11,181,988 100% $8,198,872 $1,463,070 $9,661,942 100% $10,023,667  $2,243,718  $12,267,385   100% $9,648,831  $1,533,157  $11,181,988   100%

 

Prior period amounts have not been adjusted under the modified retrospective approach.

 

Under ASC Topic 606, the Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to receive in exchange for the product or service.

 

Product sales consist of a single performance obligation that the Company satisfies at a point in time. All transactions in the radiochemical productsTheranostics Products and nuclear medicine standards segments fall into this category. Most sales transactions in the cobalt products business segment fall into this category but other cobalt product sales are recorded as deferred income as discussed below. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the Company’s historical practices and shipping terms specified in the sales agreements and invoices, these criteria are generally met when the products are:

 

Invoiced.

•      Invoiced.

•      Shipped from the Company’s facilities (“FOB shipping point”, which is the Company’s standard shipping term). For these sales, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped.

 

The Company’s revenue consists primarily of products manufactured for use in the nuclear medicine industry, distribution of radiochemicals and radiopharmaceuticals, and cobalt source manufacturing, and providing radiological services on a contract basis for customers.manufacturing. With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue on the Company’s consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated ship dates. For the year ended December 31, 2022,2023, the Company reported current unearned revenue of $879,365.$932,682. For the period ended December 31, 2021,2022, the Company reported current unearned revenue of $907,953$879,365. These unearned revenues will be recognized as revenue in the periods during which the cobalt shipments take place.

 

Contract Balances

 

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2023, and December 31, 2022 and December 31, 2021,, accounts receivable totaled $1,596,886$1,469,298 and $853,675,$1,596,886, respectively.

 

Practical Expedients

 

The Company has elected the practical expedient not to determine whether contacts with customers contain significant financing components.

 

F-23 

F- 24

NOTE 15 – SEGMENT INFORMATION

 

Information related to the Company’s reportable operating business segments is shown below. The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies.

Corporate Allocation

Operating Segments

 

The Company has identified the following business segments:

 

·

The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry and includes consolidated reporting of the wholly-owned subsidiaries RadQual and TI Services.

 

·

The Cobalt Products segment includes management of a cobalt irradiation contract, fabrication of cobalt capsules for teletherapy or irradiation devices, and recycling of expended cobalt sources.

 

·

The Theranostics Products Segment (formerly called the Radiochemical Products segmentSegment) includes production and distribution of Iodine-131Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, or research applications. These products are either directly produced by the Company or are purchased in bulk from other producers and distributed by the Company in customized packages and chemical forms tailored to customer and market demands.  Iodine-131Iodine-131 is the predominant radiochemical sold in this segment.

 

·

The Fluorine Products segment historically involved the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. During 2013, these testing activities were completed, and the pilot plant facility was closed.  The Company has developed or acquired all patent rights to these processes. Future work in this segment will involve license support and, as financing permits, further work related to the de-conversion facility.

 

F- 25

The following presents certain segment information as of and for the years ended December 31, 20222023 and 2021:2022:

Sale of product

 

2023

  

2022

 

Theranostics products

 $6,842,898  $6,045,767 

Cobalt products

  1,037,073   1,157,536 

Nuclear medicine standards

  4,387,414   3,978,685 

Fluorine products

      

Total segments

  12,267,385   11,181,988 

Corporate revenue

      

Total consolidated

 $12,267,385  $11,181,988 

Depreciation and amortization

 

2023

  

2022

 

Theranostics products

 $25,287  $63,493 

Cobalt products

  53,331   49,202 

Nuclear medicine standards

  114,833   114,990 

Fluorine products

  115,879   115,598 

Total segments

  309,330   343,283 

Corporate depreciation and amortization

  40,764   30,913 

Total consolidated

 $350,094  $374,196 

Segment income (loss)

 

2023

  

2022

 

Theranostics products

 $3,037,375  $4,182,151 

Cobalt products

  (126,504)  (95,779)

Nuclear medicine standards

  386,592   39,223 

Fluorine products

  (105,099)  (139,860)

Total segments

  3,192,364   3,985,735 

Corporate loss

  (4,061,380)  (3,682,497)

Total consolidated

 $(869,016) $303,238 

Expenditures for segment assets

 

2023

  

2022

 

Theranostics products

 $3,420  $3,379 

Cobalt products

  49,774   17,105 

Nuclear medicine standards

  35,137   75,478 

Fluorine products

     4,100 

Total segments

  88,331   100,062 

Corporate purchases

  60,727   19,952 

Total consolidated

 $149,058  $120,014 

Segment assets

 

2023

  

2022

 

Theranostics products

 $849,351  $1,075,252 

Cobalt products

  274,513   406,629 

Nuclear medicine standards

  3,538,558   2,744,394 

Fluorine products

  4,980,118   5,147,325 

Total segments

  9,642,540   9,373,600 

Corporate assets

  7,262,547   6,870,996 

Total consolidated

 $16,905,087  $16,244,596 

F- 26

NOTE 16 – SUBSEQUENT EVENTS

 

F-24 

Segment Information - ScheduleOn February 8, 2024, International Isotopes Inc. (“INIS”) and its wholly-owned subsidiary International Isotopes Fluorine Products, Inc. (together with INIS, the “Company”) entered into an Asset Purchase Agreement (the “APA”) with American Fuel Resources, LLC (“AFR”), pursuant to which the Company agreed to sell to AFR all the assets and certain specified liabilities of Segment Reporting Information by Segment

Sale of product 2022  2021 
Radiochemical products $6,045,767  $4,275,044 
Cobalt products  1,157,536   1,354,517 
Nuclear medicine standards  3,978,685   4,002,606 
Fluorine products  —     29,775 
Total segments  11,181,988   9,661,942 
Corporate revenue  —     —   
Total consolidated $11,181,988  $9,661,942 

Depreciation and amortization 2022  2021 
Radiochemical products $63,493  $312,405 
Cobalt products  49,202   50,389 
Nuclear medicine standards  114,990   77,351 
Fluorine products  115,598   114,652 
Total segments  343,283   554,797 
Corporate depreciation and amortization  30,913   26,477 
Total consolidated $374,196  $581,274 

Segment income (loss) 2022  2021 
Radiochemical products $4,182,151  $1,171,625 
Cobalt products  (95,779)  384,800 
Nuclear medicine standards  (15,280)  432,003 
Radiological services  54,503   129,229 
Fluorine products  (139,860)  (120,421)
Total segments  3,985,735   1,997,236 
Corporate loss  (3,682,497)  (2,899,583)
Total consolidated $303,238  $(902,347)

Expenditures for segment assets 2022  2021 
Radiochemical products $3,379  $3,103 
Cobalt products  17,105   22,242 
Nuclear medicine standards  75,478   37,009 
Fluorine products  4,100   8,120 
Total segments  100,062   70,474 
Corporate purchases  19,952   —   
Total consolidated $120,014  $70,474 

Segment assets 2022  2021 
Radiochemical products $1,075,252  $2,890,590 
Cobalt products  406,629   597,420 
Nuclear medicine standards  2,741,189   2,256,024 
Radiological services  3,205   3,735 
Fluorine products  5,147,325   5,258,823 
Total segments  9,373,600   11,006,592 
Corporate assets  6,870,996   5,320,550 
Total consolidated $16,244,596  $16,327,142 

the Company’s depleted uranium deconversion and fluorine extraction plant (the “DUF6 Plant”), subject to the terms and conditions set forth in the APA (the “Transaction”). The Company expects to close the Transaction in approximately 12 to 24 months, subject to satisfaction of certain closing conditions (the “Closing”).

 

F-25 

NOTE 16 – SUBSEQUENT EVENTSThe purchase price to be paid by AFR in the Acquisition will consist of (i) $50,000 to be paid within five business days of execution of the APA (the “Prepayment”), and (ii) $12,500,000 paid at the Closing, less the Prepayment. The APA contains customary representations and warranties, covenants and indemnification provisions for a transaction of this nature. Closing of the Transaction is also subject to certain closing conditions, including (i) transfer of the U.S. Nuclear Regulatory Commission (NRC) license related to the DUF6 Plant (the “NRC License Transfer”) and (ii) transfer of Purchased Assets (as defined in the APA), which includes licenses, patents, agreements, and other records of the DUF6 Plant.

 

PursuantThe APA may be terminated, among other things, (i) upon mutual written consent by the parties to an employment agreement with its Chief Executive Officer, the Company awarded 560,000 fully vested sharesAPA, (ii) by either party upon material breach of common stockthe APA by the other party, subject to its Chief Executive Officer in February 2023 under the 2015 Plan. The number of shares awarded was based on a $28,000 stock award using a price of $0.05 per share. The employment agreement providesapplicable cure periods, and (iii) by AFR if there is reason to believe that the number of shares issuedNRC License Transfer will notbe based on completed by March 31, 2026.

In February 2024, the average closing price of common stock for2013 Promissory Note was modified to extend the 20 trading days priormaturity date to issueMarch 31, 2026, with all remaining terms unchanged.

In February 2024, the 2018 Promissory Note was modified to extend the maturity date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grantMarch 31, 2026, with all remaining terms unchanged.

In February 2024, the 2019 Promissory Note was $22,400, which was determined by multiplyingmodified to extend the number of shares awarded by the closing price of the common stock on February 28, 2021, which was $0.04 per share. The Company withheld 219,240 shares of common stockmaturity date to satisfy the employee’s payroll tax obligations in connection March 31, 2026, with this issuance. The net shares issued on February 28, 2023 totaled 340,760.all remaining terms unchanged.

 

 

 

F-26

F-27